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Persistent or repeated elevation of intraocular pressure (IOP) is a primary risk 
factor of visual field loss in glaucoma, therefore IOP reduction is the first-line therapeutic 
option in the disease management. Unfortunately, the current therapies are associated 
with a lot of deficiencies including several daily dosing, reduced efficacy and systemic 
side effects all of which resulted in poor patient compliance. Previously we have 
identified Calcium voltage-gated channel auxiliary subunit Alpha2delta 1 gene 
(Cacna2d1) as a novel modulator of IOP and confirmed that pregabalin targeted 
CACNA2D1 in eye tissues (ciliary body and trabecular meshwork) to lower IOP in a 
dose-dependent manner. The research presented in this dissertation aimed to develop a 
once-daily ocular pregabalin-loaded multiple water-in-oil-in-water microemulsion eye 
drops. Several in vitro and in vivo evaluations were used to characterize the prepared 
ophthalmic formulations. Also stability study at 5°C, 25°C, 30°C and 40°C was 
conducted for four months. All the formulations components were carefully selected to 
be highly biocompatible that provided a highly transparent eye drops with a miniscule 
droplet size (<20nm) accompanied with a good shelf life stability. The special 
engineering of the microemulsion eye drops succeeded to provide a continuous 
pregabalin release for up to 24h. Slit-lamp biomicroscopic exams and the cell toxicity 
study demonstrated that the developed ocular formulations were non-toxic. The in vivo 
study using Dutch belted rabbits showed that the microemulsion formulation markedly 
enhanced the efficacy and prolonged the duration of pregabalin IOP-lowering effect. 
Interestingly, a single drop of pregabalin microemulsion induced 42.3±2.6% IOP 
reduction that returned to baseline at 32.7±1.3h from application (AUC=169.9±13.4 
mmHg.h). In the absence of the microemulsion system, the same drug produced only 
29.4±1.4% IOP reduction that returned to baseline at 9.3±0.7h (AUC=39±4 mmHg.h). 
Finally, the developed multiple microemulsion is a promising carrier that sustained the 
release and prolonged the duration of action of pregabalin and could be a carrier for any 




TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
Anatomy of the Eye .........................................................................................................1 
Eyebrows and eyelids ..................................................................................................1 
The conjunctiva ............................................................................................................1 
The eyeball ...................................................................................................................2 
The External Fibrous Layer .............................................................................................2 
The sclera (the white of the eye) ..................................................................................2 
The cornea ....................................................................................................................2 
The Intermediate Vascular/Muscular Layer ....................................................................3 
The choroid ..................................................................................................................3 
The ciliary body ...........................................................................................................3 
The iris and the pupil ...................................................................................................3 
The lens ........................................................................................................................4 
The Internal Neural Layer ................................................................................................4 
Retina ...........................................................................................................................4 
Optic nerve ...................................................................................................................4 
Chambers of the eye .....................................................................................................4 
Glaucoma .........................................................................................................................4 
Open-angle glaucoma ..................................................................................................5 
Pregabalin ....................................................................................................................5 
Microemulsion .............................................................................................................6 
Research Hypothesis ........................................................................................................8 
Aim 1: To optimize and develop a multiple W/O/W microemulsion eye drops .........8 
Aim 2: To characterize the prepared multiple W/O/W microemulsion eye drops ......8 
Aim 3: To determine the safety, in vivo efficacy and cell toxicity of our prepared 
multiple W/O/W microemulsion eye drops in Dutch belted rabbits and a human 
corneal limbal epithelial cell line .................................................................................8 
Aim 4: To determine the physical and chemical stability of our ME eye drops..........9 
CHAPTER 2. OPTIMIZATION AND DEVELOPMENT OF A MULTIPLE 
WATER IN OIL IN WATER MICROEMULSION EYE DROPS ............................10 
Introduction ....................................................................................................................10 
Types of microemulsion ............................................................................................10 
Formation of MEs ......................................................................................................11 
Materials and Methods ...................................................................................................13 
HPLC analysis of pregabalin .....................................................................................13 
Solubility determination of pregabalin ......................................................................15 
Preparation of the Multiple ME Eye Drops ...................................................................15 
Construction of ternary phase diagrams and preparation of the primary W/O ME ...15 
Preparation of external aqueous phase and incorporation of the bioadhesive 
polymers .....................................................................................................................16 




Our constructed ternary and pseudo-ternary phase diagrams ....................................18 
The external aqueous phase surfactant/co-surfactant mixture composition ..............20 
Pregabalin solubility ..................................................................................................22 
CHAPTER 3. IN VITRO CHARACTERIZATION OF THE PREPARED 
PREGABALIN-LOADED W/O/W ME EYE DROPS .................................................23 
Introduction ....................................................................................................................23 
Materials and Methods ...................................................................................................23 
Measurement of the pH ..............................................................................................24 
Average droplet size, polydispersity index (PDI) and zeta potential measurement ..24 
Transmission electron microscopy ............................................................................24 
Determination of the viscosity ...................................................................................24 
Measurement of the bioadhesive force ......................................................................25 
In vitro drug release ...................................................................................................25 
Corneal permeability study ........................................................................................25 
Immunohistochemistry (IHC) ....................................................................................26 
Results ............................................................................................................................27 
Average droplet size, PDI and zeta potential .............................................................27 
TEM ...........................................................................................................................27 
Viscosity and bioadhesion .........................................................................................27 
In vitro release ............................................................................................................30 
Corneal permeability ..................................................................................................32 
Immunohistochemistry ..............................................................................................33 
CHAPTER 4. DETERMINATION OF SAFETY, IN VIVO EFFICACY AND 
THE CELL TOXICITY OF THE MICROEMULSION EYE DROPS .....................37 
Methods .........................................................................................................................37 
Animals ......................................................................................................................37 
In vivo evaluation of our formulation safety .............................................................37 
In vivo evaluation of our formulation efficacy ..........................................................39 
In vitro evaluation of formulation cell toxicity ..........................................................39 
Results ............................................................................................................................40 
In vivo safety and efficacy .........................................................................................40 
In vitro cytotoxicity ....................................................................................................44 
CHAPTER 5. STABILITY STUDY OF PREGABALIN-LOADED CARBOPOL 
981 ME EYE DROPS ......................................................................................................48 
Introduction ....................................................................................................................48 
Physical Stability ...........................................................................................................49 
Freeze-thaw cycles .....................................................................................................49 
Centrifugation test ......................................................................................................49 
Chemical Stability ..........................................................................................................49 
pH of the prepared multiple ME formulation ............................................................50 
Drug content of the prepared multiple ME formulation ............................................50 
Average droplet size, PDI and zeta potential .............................................................50 




Physical stability ........................................................................................................51 
pH of our multiple ME eye drops ..............................................................................51 
Average droplet size, polydispersity index (PDI) and zeta potential .........................51 
Drug content ...............................................................................................................57 
In vitro release ............................................................................................................61 
CHAPTER 6. DISCUSSION AND CONCLUSION .....................................................64 
Future Directions ...........................................................................................................64 
Aim 1: To optimize and develop a multiple W/O/W microemulsion eye drops .......64 
Aim 2: To characterize the prepared multiple W/O/W microemulsion eye drops ....65 
Aim 3: To determine the safety, in vivo efficacy and cell toxicity of our prepared 
multiple W/O/W microemulsion eye drops in Dutch belted rabbits and a human 
corneal limbal epithelial cell line ...............................................................................67 
Aim 4: To determine the physical and chemical stability of our ME eye drops........68 
Conclusion .....................................................................................................................68 





LIST OF TABLES 
 
Table 2-1.  Composition of pregabalin-loaded bioadhesive multiple W/O/W ME .........17 
Table 3-1.  Droplet size, PDI and zeta potential of blank and medicated ME 
formulations .................................................................................................28 
Table 3-2.  In vitro transcorneal permeability parameters of pregabalin from 
multiple W/O/W ME and control .................................................................34 
Table 4-1.  Pharmacodynamic parameters after application of 0.6% pregabalin-
loaded ME chitosan, sod. alginate, Carbopol 981 and control eye drops 
to Dutch belted rabbits .................................................................................42 
Table 4-2.  Statistical comparisons among different pregabalin ME eye drops and 
the control after application of a single dose ................................................43 
Table 5-1.  The pH values of our developed pregabalin-loaded ME eye drops at 
different temperatures after four month of stability study ...........................53 
Table 5-2.  Statistical comparisons among pH values of pregabalin-loaded Carbopol 
ME eye drops stored at four different temperatures and the initial pH 
value of the same formulation ......................................................................53 
Table 5-3.  The average droplet size of our prepared pregabalin-loaded ME eye 
drops at different temperatures after four month of stability study ..............55 
Table 5-4.  Statistical comparisons among droplet size values of pregabalin-loaded 
Carbopol ME eye drops stored at four different temperatures and the 
initial droplet size value of the same formulation ........................................55 
Table 5-5. The average polydispersity index of our prepared pregabalin-loaded ME 
eye drops at different temperatures after four month of stability study .......56 
Table 5-6.  Statistical comparisons among PDI values of pregabalin-loaded 
Carbopol ME eye drops stored at four different temperatures and the 
initial droplet size value of the same formulation ........................................58 
Table 5-7.  The average zeta potential of our prepared pregabalin-loaded ME eye 
drops at different temperatures after four month of stability study ..............59 
Table 5-8.  Statistical comparisons among the zeta potential values of pregabalin-
loaded Carbopol ME eye drops stored at four different temperatures and 
the initial zeta potential value of the same formulation ...............................59 
 
x 
Table 5-9.  The percentage amount remaining of pregabalin in our prepared 
pregabalin-loaded ME eye drops at different temperatures after four 
month of stability study ................................................................................60 
Table 5-10.  Statistical comparisons among the percentage amount remaining of 
pregabalin values of pregabalin-loaded Carbopol ME eye drops stored at 
four different temperatures and the initial value of the same formulation ...60 
Table 5-11.  Statistical comparisons among the cumulative amounts released of 
pregabalin after four months of stability and the initial values of the 





LIST OF FIGURES 
 
Figure 1-1. Subunit assembly of voltage-gated calcium channels ....................................7 
Figure 2-1.  Schematic of the effect of temperature (T) or salinity (S) and the 
concentration of surfactant on ME type .......................................................12 
Figure 2-2.  Schematic of the energetics involved in a typical microemulsion disperse 
system ...........................................................................................................14 
Figure 2-3.  Ternary and pseudo-ternary phase diagrams of the primary W/O ME .........19 
Figure 2-4.  Cartoon showing composition of pregabalin-loaded multiple W/O/W 
ME eye drops ...............................................................................................21 
Figure 3-1.  TEM image of pregabalin-loaded ME ..........................................................29 
Figure 3-2.  Viscosity and bioadhesion of pregabalin-loaded ME formulations and 
controls .........................................................................................................29 
Figure 3-3.  Cumulative amount released (%) of pregabalin from ME eye drops ...........31 
Figure 3-4.  Cumulative amount permeated of pregabalin from ME eye drops using 
rabbit cornea .................................................................................................34 
Figure 3-5.  Transcorneal flux of pregabalin from pregabalin-loaded ME eye drops ......35 
Figure 3-6.  Cellular localization of CACNA2D1 in Dutch belted rabbits eye ................36 
Figure 4-1.  IOP reduction (%) after application of pregabalin simple eye drops ............38 
Figure 4-2.  IOP reduction (%) after 0.6% pregabalin ME eye drops application in 
Dutch belted rabbits .......................................................................................41 
Figure 4-3.  Slit lamp examination after application of pregabalin-loaded ME eye 
drops .............................................................................................................45 
Figure 4-4.  Cytotoxicity histogram of pregabalin-loaded Carbopol ME eye drops using 
HCLE ............................................................................................................46 
Figure 5-1.  The pH of pregabalin-loaded Carbopol ME eye drops at different 
temperatures after four month of stability study ..........................................52 
Figure 5-2.  The mean droplet size of pregabalin-loaded ME eye drops at different 
temperatures after four month of stability study ..........................................54 
Figure 5-3.  The PDI of pregabalin-loaded Carbopol ME eye drops at different 
temperatures after four month of stability study ..........................................56 
 
xii 
Figure 5-4.  The zeta potential of pregabalin-loaded Carbopol ME eye drops at 
different temperatures after four months of stability study ..........................58 
Figure 5-5.  Cumulative amount released (%) of pregabalin from Carbopol ME eye 




LIST OF ABBREVIATIONS 
 
 
AUC total  Area under the curve (total) 
BCS Biopharmaceutics classification system 
CB Ciliary body 
DMSO Dimethyl sulfoxide 
HCLE Human corneal limbal epithelial cells 
HLB Hydrophilic-lipophilic balance 
ICH International Conference on Harmonisation 
IOP Intraocular pressure 
LOA List of Abbreviations (sample 2nd entry) 
ME Microemulsion 
MTT Methylthiazolyldiphenyl tetrazolium 
O/W Oil in water 
PDI Polydispersity index 
POAG Primary open-angle glaucoma 
PRG Pregabalin 
Tend Time required for IOP to return again to its baseline 
TM Trabecular meshwork 










CHAPTER 1.    INTRODUCTION 
 
 
Topical application of drugs as eye drops (simple drug solutions) is the most 
advantageous route for ocular drug delivery to treat various eye diseases affecting the 
anterior segment of the eye. Because of the simplicity and the avoidance of the systemic 
absorption that led to a good patient acceptance, these conventional ophthalmic dosage 
forms account for nearly 90% of the currently available marketed ocular formulations (1). 
However the extensive and rapid precorneal loss of most of the applied volume of eye 
drops caused by the high tear fluid turnover and the rapid drainage limited the efficiency 
and the intraocular bioavailability of these topical formulations (2-4). 
 
Ocular drug delivery is one of the most challenging research areas because of the 
unique structure of the eye and the specific environment available for drug application. 
It’s very important to study the anatomy of the eye before designing an efficient new 
ocular drug delivery system as a therapy for various eye disorders. 
 
 
Anatomy of the Eye 
 




Eyebrows and eyelids 
 
The eyebrows are well known for its importance for facial expression and human 
communication. Also, it helps to prevent the falling of debris, water and sweat down into 
the eye socket. Coming to the eyelids as a protective cover for the eyeball, it also helps to 





The conjunctiva is a thin semi-transparent moist mucous membrane that 
originates at the corneoscleral junction. Conjunctiva consists of two portions; the first one 
that covers the inner side of the eyelids (the palpebral conjunctiva) and the second portion 
that covers the front surface of the eyeball except the central clear cornea (the bulbar 
conjunctiva). It composed of multilayered epithelium on top of vascularised connective 
tissue (5). The conjunctiva contains many glands which are involved in normal 
physiological processes such as the accessory glands of Wolfring and Krause. The 
function of the conjunctiva is to produce mucous as well some components of the tear 







It is mainly made up of three layers:  
 
1. The external fibrous layer that includes sclera, cornea, limbus, trabecular 
meshwork and canal of Schlemm. 
 
2. The intermediate vascular/muscular layer that consists of two parts; (iris-ciliary 
body) and posterior (choroid). 
 
3. The internal neural layer (the sensory part of the eye) includes chambers of the 
eye, retina, optic nerve and macula. 
 
 
The External Fibrous Layer  
 
This outer layer of the eyeball consists of relatively tough fibrous tissues made up 
of collagen and elastin. It comprises: 
 
 
The sclera (the white of the eye)  
 
It is a dense, opaque white, fibrous structure constitutes the posterior five- sixth of 
the globe It consists of three layers; episclera, sclera proper and lamina fussa. It contains 
few blood vessels and provides the structural integrity of the eye.  
 
 
The cornea  
 
It is the transparent tissue that covers the pupil, the iris and lens. The thickness of 
the healthy cornea is 0.5-0.8 mm with a radius of 11-12 mm. Because of the difference in 
the structural organization of the collagen fibers in the cornea and the sclera, one is clear 
while the other is opaque, respectively. Collagen fibers are arranged in highly regular 
laminae while it appear interwoven and extend in all directions in the sclera (7). Morever, 
there are no blood vessels in the cornea and oxygen is mainly provided by diffusion so it 
is transparent for optimal visual acuity (6). Furthermore, the function of the cornea is to 
control and focus the light entering the eye by working as a window. The cornea is 
composed of five layers: the outermost epithelium, Bowman's layer, the middle corneal 
stroma, Descemet's membrane, and innermost endothelium. The corneal epithelium is the 
rate-limiting barrier that restricts the permeation of hydrophilic and large molecules 
because of the tight junctions in the most superficial cells (8, 9). The corneal epithelium 
is covered by the pre-corneal tear film, which ensures nutrition of the anterior surface of 
the cornea. The permeation of very lipophilic drugs may be restricted by the highly 
permeable hydrophilic stroma due to the limited partitioning from the epithelium to the 
stroma (8, 10). Descemet's membrane is the acellular basement membrane of the corneal 




 The corneal endothelium is a monolayer that regulates fluid transport from the 
aqueous humor. In ocular drug absorption, the corneal endothelium is not considered a 
significant barrier. For topically applied drugs the cornea and the conjunctiva are the 
major tissue barriers that restrict their ocular absorption but with a variable contribution 
(11).  
 
 Limbus is a transitional zone 1-2 mm wide between the cornea, the sclera and 
conjunctiva. It includes the trabecular meshwork and the canal of Schlemm.  The 
trabecular meshwork surrounds the circumference of the anterior chamber. It is a porous-
like structure with opening diameter 2-3 μm through which the aqueous humor flows into 
the canal of Schelmm which is an oval-shaped channel that covers the entire 
circumference of the anterior chamber. It connected to the anterior chamber with the 
trabecular meshwork.  
 
 
The Intermediate Vascular/Muscular Layer 
 





The choroid is a rich vascular layer that supplies oxygen and nutrients to the outer 
layers of retina and the structures of the anterior chamber. It extends from the optic nerve 
posteriorly to the ciliary body anteriorly.  
 
 
The ciliary body 
 
The ciliary body extends from the iris to the choroid. It is divided into two 
portions; the uveal portion and the epithelial portion. The main functions of the ciliary 
body are to secrete aqueous humor and to allow the eye to adjust distant objects in order 
to obtain a clear image on the retina.  
 
 
The iris and the pupil 
 
The iris is the colored tissue of the eye. It is located in front of the lens and the 
ciliary body. It separates the anterior and posterior chambers. Its main function is to 
regulate the amount of the light entering the eye via dilation and constriction to ensure 
clear vision (6). A central opening in the iris is the pupil which controls the amount of 
light admitted to the eye. The color of the iris that is responsible for eye's color depends 







The lens is a crystalline, transparent biconvex structure located behind iris and the 
pupil aperture and in front of the vitreous body. It is suspended by zonular fibers and is 
about 4 mm thick and 10 mm diameter. It does not have any blood vessels, nerve fibers, 
or connective tissue, and is nourished by the aqueous humor surrounding it.  
 
 
The Internal Neural Layer 
 
It’s the innermost layer of the eyeball. It has many layers of cells including retina, 





It is a complex, densely interconnected, 10 layered tissue which is an extension of 
the central nervous system. It contains two types of photoreceptor cells—rods and 
cones—which transfer impulses from the retina to the brain visual cortex via the optic 
nerve. Rods are responsible for black and white vision during dim light. While, cones are 





The optic nerve is a portion of the central nervous system consisting of axons of 
retinal ganglion cells together with nerve fibers that extend from the brain visual cortex to 
the eye.  
 
 
Chambers of the eye 
 
Internally the eye is made up of two unequal compartments: a smaller 
compartment that lies anterior to the eye lens termed the aqueous compartment, and a 
larger (vitreous) compartment that lies behind the lens. The aqueous compartment is 
further divided into an anterior and a posterior chamber by the iris (Presland, 2007).  
 
Macula is a small specialized yellow pigmented zone in the retina with a diameter 
of 7 mm. It is responsible for central or reading vision. Its main function is to allow to see 





Glaucoma is a multifactorial eye disease that can cause optic nerve damage and 




can be defined as a group of ocular diseases that may cause characteristic, progressive 
changes in the optic nerve head, visual field loss, or both (12, 13). There are several types 
of glaucoma while among all these types, primary open-angle glaucoma (POAG) is the 
most common form that accounts for at least 90% of all glaucoma cases all over the 
world (14, 15). Treatment of glaucoma depends upon the nature and severity of each 
case. In general, glaucoma cannot be cured, but it can be controlled. Topical eye 
preparations, oral preparation, laser procedures, and surgical operations are used to 
prevent or slow further damage. Also, with any type of glaucoma, regular eye 





It is also called primary or chronic glaucoma. The term open-angle means that the 
angle where the iris meets the cornea is patent. Elevated IOP is one of the most 
significant risk factors contributing to visual field loss in primary open angle glaucoma. 
IOP is generated by the balance of aqueous humor production by the ciliary body (CB) 
and its drainage through the trabecular meshwork (TM) (conventional pathway), and to a 
lesser degree the unvisceral or nonconventional pathway. An imbalance between the 
inflow and outflow of aqueous humor leads to a change in IOP (17, 18). Open-angle 
glaucoma has several characteristics. It is a lifelong condition that develops very slowly. 
In addition, its symptoms and resultant damage are usually not noticed by the patient 
until significant visual field loss has occurred. Lastly, it has a wide angle between the iris 
and the cornea (19). The only treatment of open-angle glaucoma, aside from surgery, is 
IOP-reducing drugs applied topically onto the cornea. Unfortunately, several daily 
applications of such drugs are necessary to maintain reduced IOP, which can be 
accompanied by poor patient satisfaction/compliance and potential toxicity to the anterior 
structures of the eye. 
 
Despite the availability of several POAG approved drugs, such as carbonic 
anhydrase inhibitors, prostaglandins, and beta-blockers, yet these agents are not a cure. 
They are not universally effective in reducing IOP and are laden with various side effects. 
Accordingly, patient compliance is low and visual deterioration is frequent, resulting in 
severe impairment and blindness in millions of people around the world. So the 
availability of an effective drug with minimal or no side effects is still urgent unmet 





 It is (S)-3-aminomethyl-5-methylhexanoic acid, a gabapentinoid drug. It has been 
clinically effective in treating epileptic seizures or neuropathic pain disorders such as 
fibromyalgia and diabetic peripheral neuropathy (20, 21). Pregabalin has become a lead 
molecule due to its hydrophilicity, rapid absorption after oral administration and high 
bioavailability (~90%) (22). It is currently marketed by Pfizer (NY, USA) as Lyrica®. 




as a class I drug (highly soluble and highly permeable) (23). Pregabalin binds with high 
affinity and high selectivity to the CACNA2D1 subunit of the voltage-dependent calcium 
channels (Figure 1-1) in eye tissues (trabecular meshwork and ciliary body) and lowers 
IOP in POAG (24). 
 
 Of course, eye drops are the most commonly used and acceptable topical 
ophthalmic dosage form all over the world (1, 25). When the active ingredient is a water-
soluble drug, this dosage form usually consists of a simple drug solution. The prevalence 
of this dosage form may be due to the ease of manufacturing and the ease of application 
into the eye. Unfortunately, this dosage form suffers from several drawbacks that may 
result in absorption of only 5% of the administered dose into the eye tissues (26, 27). 
These drawbacks include, the rapid drainage from the eye surface either to the outside of 
the eye or to the systemic circulation through nasolacrimal duct and the very short 
corneal contact time (28). Additionally, the high blood perfusion of theconjunctiva leads 
to systemic absorption of a large fraction of the drug that was absorbed through this 
tissue. Several daily applications may overcome these drawbacks, yet they usually result 
in exaggeration of the systemic side effects and lower patient satisfaction and compliance 
that may cause the patient to discontinue the drug use and worsen his/her visual loss. 
 
Several formulations strategies have been used to overcome the drawbacks 
associated with aqueous solution eye drops among them; viscosity-inducing agent (29-
31), penetration enhancers (32), bioadhesive polymers (33), ocular implants (26, 34, 35), 
contact lenses (36, 37), ocular inserts (38), ocular injections (39, 40) and colloidal drug 
delivery systems such as liposomes, nanosuspensions, microparticles, nanoparticles, 
nanoemulsions and microemulsions (41). All the listed systems may sustain drug release 
and/or prolong the corneal contact time. Among all these systems, microemulsions offer 





Microemulsion (ME) can be defined as a single-phase, optically clear, isotropic, 
thermodynamically stable, system with droplet size in the submicron range (10-100 nm 
diameter) (42-45).  MEs are stabilized by a surfactant which is an amphiphilic compound 
usually used in combination with a co-surfactant, which may be an amine, a short chain 
alcohol or another weakly amphiphilic molecule (46, 47). 
 
MEs are considered one of the most promising carriers for ocular drug delivery by 
offering several advantages including thermodynamic stability (48), optical clearance, 
ease of preparation and scaling up (49), few synthesis steps, small energy requirement 
during their preparation, 100% encapsulation efficiency, compatibility with both water-
soluble and water-insoluble drugs and improved bioavailability through facilitating drug 
transcorneal permeability (50). 
 
MEs are considered one of the most promising carriers for ocular drug delivery by 






Figure 1-1. Subunit assembly of voltage-gated calcium channels 
 
Graphic representation of the high voltage-activated calcium channel complex consisting 
of the main pore forming α1 (blue) subunit plus ancillary, β (blue), γ (blue), and α2 (red) 
and δ1 (red) subunits. α2 and δ1 subunits have a disulphide bond between them.  
Reprinted with permission. Chintalapudi SR, Maria D, Di Wang X, Bailey JNC, 
consortium N, International Glaucoma Genetics c, et al. Systems genetics identifies a role 
for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility. Nat 






ease of preparation and scaling up (49), few synthesis steps, small energy requirement 
during their preparation, 100% encapsulation efficiency, compatibility with both water-
soluble and water-insoluble drugs and improved bioavailability through facilitating drug 
transcorneal permeability (50). 
 
Our recently published work showed that pregabalin generates an IOP-lowering 
response in both mice and rabbits after instillation of pregabalin simple eye drops (24). 
Unfortunately, the hydrophilicity of the drug may hinder its ophthalmic use, as it may 
lower its ocular bioavailability when applied in the form of an aqueous drug solution. In 
this study, we seek to overcome this problem by incorporating pregabalin in the 
innermost layer of our multiple ME, which will delay its release as it has to pass through 
several interfaces of the ME and the outermost layer includes a bioadhesive polymer. 
Based on this strategy, we predict that our new formulations could sustain the release of 





We hypothesized that a new topical microemulsion bioadhesive ophthalmic 
formulation can sustain the release of pregabalin as a novel glaucoma therapy. The 
studies presented in Chapters 2-5 address the following specific aims: 
 
 
Aim 1: To optimize and develop a multiple W/O/W microemulsion eye drops 
 
1. What is the proper surfactant mixture and its ratio that shows the largest ME 
region in the pseudo-ternary phase diagram? 
2. How we can optimize and develop a multiple water-in-oil-in-water ME eye drops 
by incorporating a bioadhesive polymer in the external aqueous phase? 
 
 
Aim 2: To characterize the prepared multiple W/O/W microemulsion eye drops 
 
1. Can we sustain the in vitro release of pregabalin by incorporation of the drug in 
the innermost layer of the developed multiple W/O/W ME?  
2. Can we determine how our developed formulations affect the corneal 
permeability of pregabalin compared to the control? 
 
 
Aim 3: To determine the safety, in vivo efficacy and cell toxicity of our prepared 
multiple W/O/W microemulsion eye drops in Dutch belted rabbits and a human 
corneal limbal epithelial cell line  
 
1. Can we determine the safety and in vivo efficacy of our prepared multiple 





2. Do our developed ophthalmic formulations have any level of cell toxicity to a 
human corneal limbal epithelial cell line? 
 
 
Aim 4: To determine the physical and chemical stability of our ME eye drops 
 
1. Do our multiple ME eye drops will remain physically stable after both freeze-
thaw cycles and centrifugation tests? 
2. What is the shelf life and the expiration date of our ME eye drops after a long-




CHAPTER 2.    OPTIMIZATION AND DEVELOPMENT OF A MULTIPLE 





In emulsion systems, MEs exhibit the smallest droplet sizes (10-100 nm in 
diameter) compared to both macro- and nanoemulsions. MEs are considered a unique 
colloidal drug delivery system for various routes of administration (51). It has the ability 
to deliver both hydrophilic and lipophilic (52) drugs with improved bioavailability and 
stability. Also, these systems are formed spontaneously (53) without the need of energy 
input offering a very easy and cheap production process (54). 
 
There are four classes of surfactants, non-ionic (Tweens), anionic (sodium 
dodecyl benzene sulfonate), cationic (quaternary ammonium salt) and zwitterionic 
(amphoteric e.g lecithin). The formation of MEs requires a relatively high concentration 
of surfactants (i.e., 15–30% w/w of the oil phase) in contrast to nanoemulsions that 
require less surfactant (1–3% of the volume of the oil phase) (55, 56). A surfactant works 
mainly through reducing the interfacial tension between the oil and water phases and 
hence lowers the energy required to increase the surface area. Non-ionic surfactants are 
more preferred in ME formulation due to their safety profile compared to ionic 
surfactants. In addition, non-ionic surfactants are more resistant to pH changes in 
comparison to other classes of surfactants (57).  
 
 
Types of microemulsion 
 
According to Winsor classification there are four general types of MEs (58, 59):  
 
1. Type I - biphasic ME with the surfactant preferentially soluble in water and oil-in-
water (O/W) MEs form. However, in this Winsor I type of ME there is an excess 
upper oil phase where surfactant is only present as monomers at the interface that 
separated this oil phase with surfactant-rich aqueous phase. 
 
2. Type II - biphasic ME where the surfactant is mainly soluble in the oil phase and 
water-in-oil (W/O) MEs form. Meanwhile, in this Winsor II type of ME an excess 
aqueous phase coexists with the surfactant-rich oil phase. 
 
3. Type III - triphasic ME where surfactant-rich middle bicontinuous ME coexists 
with both the upper excess oil phase and the lower excess water phase (surfactant-
poor phases) (44, 59). 
 
4. Type IV- monophasic, it’s a single phase micellar solution. This type of ME is 
spontaneously formed upon addition of sufficient concentration of 




 Depending on the emulsifier used, MEs can transition between each type quite 
easily by increasing the temperature in case of non-ionic surfactant or a simple change in 
salinity (electrolyte concentration) for ionic surfactant. In general, MEs follow trends 
displayed in Figure 2-1, typically referred to as a fish diagram (45).  
 
A multiple ME is a multiple dispersion system where both hydrophobic and 
hydrophilic surfactants are incorporated during the preparation steps. So, it could be 
considered as ME of ME. There are two types of multiple ME: 
 
1. Water-in-oil-in-water (W/O/W) ME: This multiple type of ME contains both W/O 
and O/W simple ME. Thus, the disperse system have small water droplets that are 
entrapped within larger oil droplets that in turn are dispersed in a continuous 
external aqueous phase. Furthermore, this unique structure of multiple ME make 
it very appropriate to sustain the release of water soluble drugs that are 
incorporated in the internal water droplets as it will act as a reservoir for the drug. 
 
2. Oil-in-water-in-oil (O/W/O) ME: This type of multiple ME contains both O/W 
and W/O simple ME. Thus, the disperse system have small oil droplets that are 
entrapped within larger water droplets that in turn are dispersed in a continuous 
external oil phase. 
 
The hydrophilic-lipophilic balance (HLB) of a non-ionic surfactant is one of the 
most important parameters that should be considered for the proper selection of 
surfactants for a specific type of ME formulation during the early screening stage (60). 
The HLB can be calculated based on the structure of the surfactant with respect to the 
relative proportions of both hydrophilic and hydrophobic moieties within the molecule 
(61). A high HLB (>10) of a surfactant indicates high hydrophilicity that will be optimal 
for O/W microemulsion formation. Also, a hydrophobic surfactant with a low HLB (≤5) 
is used during the preparation of W/O microemulsion. 
 
During the preparation of MEs, co-surfactants are used to help to decrease the 
concentration of the surfactant required during the formulation as it increase the fluidity 
of the interface and decrease the interfacial tension through improved packing (62). 
Glycols are the most commonly used co-surfactant with a carbon chain length ranging 
from C2-C10 (e.g propylene glycol). Also, alcohols with low molecular weight (n-
butanol) and amines with short carbon chain are used as co-surfactants (59). 
 
 
Formation of MEs 
 
The formation of most MEs occurs spontaneously in the presence of the proper 
type and the specified concentration of a surfactant/co-surfactant without energy input 
(54, 63, 64). Hence, the resulted colloidal dispersion is thermodynamically stable due to 
the very low interfacial tension between the oil phase and the aqueous phase (65). Also, 
as energy is not required for ME formation, the ME production in a large scale will be 






Figure 2-1.  Schematic of the effect of temperature (T) or salinity (S) and the 
concentration of surfactant on ME type 
 
MEs can transition between each type quite easily by increasing the temperature in case 
of non-ionic surfactant or a simple change in salinity (electrolyte concentration) for ionic 
surfactant. 
Reprinted from Int J Pharm, 526(1-2), Callender SP, Mathews JA, Kobernyk K, Wettig 
SD, Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery, 425-





and aqueous phases) are at higher energetic state than that of the final ME product 
(Figure 2-2). Thus, energy is required for ME breaking into its original components. 
 
 For many years, MEs were reported to remain stable without showing any forms 
of instability (coalescence, creaming and breaking) (47, 66). In contrast, macroemulsion 
formulations have a strong tendency for creaming, flocculation and coalescence as a form 
of thermodynamic instability (67). Lv et al., 2005 reported that they were able to 
successfully increase the chloramphenicol stability by incorporating the drug into an O/W 
ME ocular drug delivery system compared to the commercial eye drops (68). 
 
Poor biopharmaceutical properties of more than 40% of drugs including poor 
water solubility hinder their marketing. In case of water-insoluble drugs, MEs can bring 
them into solution by dissolving them in suitable oil, which is then emulsified into water 
(O/W) to give a stable clear aqueous solution of such water-insoluble drug (50, 69, 70). 
On the other hand, if the drug is water-soluble and suffers from rapid absorption and/or 
removal from the biological membranes, MEs can sustain their release for longer time.  
 
The aim of this present work was to develop pregabalin-loaded multiple W/O/W 
bioadhesive ME stabilized by a combination of non-ionic hydrophilic and hydrophobic 
surfactants by the construction of ternary and pseudo-ternary phase diagrams. 
 
 
Materials and Methods 
 
Pregabalin (≥97% purity), pluronic® F-68 (poloxamer 188; polyoxyethylene-
polyoxypropylene block copolymer), chitosan (low molecular weight, 75-85% 
deacetylated), glacial acetic acid, Cremophore® EL (Kolliphor® EL, polyoxyl castor oil) 
were purchased from Sigma-Aldrich (St. Louis, MO). Propylene glycol, Tween 80 
(polysorbate 80), phosphoric acid, methanol and acetonitrile (HPLC grade) were 
purchased from Fisher Scientific (Fair Lawn, NJ). Gift samples of Labrafac lipophile 
WL1349, Capryol 90, transcutol P and Labrasol were obtained from Gattefossé 
Corporation (Paramus, NJ). Soybean L-α-Lecithin (97.7% phosphotidyl choline) was 
purchased from Calbiochem (Billerica, MA). Ethyl alcohol was purchased from Decon 
Labs, Inc. (King of Prussia, PA). Sodium alginate (viscosity of 1% solution at 25°C = 5 – 
40 cP) was purchased from MP Biomedicals (Solon, OH). Carbopol 981 was obtained as 
a gift sample from Lubrizol advanced materials, Inc. (Cleveland, OH). 
 
 
HPLC analysis of pregabalin 
 
A previously published reversed phase HPLC method was used for quantification 
of pregabalin through all experiments (71). Agilent 1100 series HPLC instrument 
(Germany) was equipped with Supelco kromasil C18 column (5µm, 100°A, 4.0 mm x 
300 mm) that was operated at 25 °C. The mobile phase consisted of a mixture of 
methanol: acetonitrile: 0.02M dipotassium hydrogen orthophosphate in the ratio of 






Figure 2-2.  Schematic of the energetics involved in a typical microemulsion 
disperse system 
 
The ME is thermodynamically stable because the ME product is at a lower energy state 
than that of its separated phases or starting components. However, nanoemulsions have a 
reversed profile with the nanoemulsion product at a higher energy state than the starting 
components.  
Reprinted from Int J Pharm, 526(1-2), Callender SP, Mathews JA, Kobernyk K, Wettig 
SD, Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery, 425-






detector and pregabalin was detected after a retention time of 5.4 min at a detection 
wavelength of 210 nm. 
 
 
Solubility determination of pregabalin  
 
Solubility screening of pregabalin in different media as well as the non-aqueous 
ingredients of our ME was carried out in order to determine its maximum solubility in 
each ingredient (72). The used media were including: Labrafac lipophile WL 1349, 
(Capryol 90 & soybean lecithin, 1:1 weight ratio mixture), water, 0.01N HCL and 0.01N 
NaOH. An excess amount of the drug was added to 2 ml of each medium in screw capped 
glass bottles. Suspensions were shaken at 180 rpm for 7 days in a thermostatically 
controlled shaker at 25±0.5°C. The obtained suspensions were allowed to equilibrate for 
further one day. After equilibration, suspensions were filtered through 0.45μm membrane 
filters (Millipore, Billerica, MA) and the filtrate was suitably diluted with the mobile 
phase then assayed for its drug content by HPLC. In case of oil and surfactant media, the 
filtrate was diluted with absolute ethanol before HPLC assay. Each experiment was 
performed in triplicate and the results were calculated as mean±SD. 
 
 
Preparation of the Multiple ME Eye Drops 
 
Preparation of our multiple ME eye drops was achieved by emulsification method 
in three steps. The first step included the formation of the primary W/O ME. The second 
step involved the preparation of the bioadhesive external aqueous phase. Finally, the 
primary W/O ME was further emulsified by drop wise addition into the bioadhesive 
external aqueous phase to produce the final bioadhesive multiple ME eye drop 
 
 
Construction of ternary phase diagrams and preparation of the primary W/O ME 
 
The primary W/O ME usually consists of an oil phase, aqueous phase, and single 
surfactant or surfactants mixture (HLB less than 7). To determine the appropriate ratio of 
each component that can efficiently produce a ME, we constructed several ternary phase 
and pseudo-ternary phase diagrams using Labrafac lipophile WL1349 as oil phase, 
MilliQ water as aqueous phase and a single surfactant (in case of ternary phase diagram) 
or surfactants mixture (in case of pseudo-ternary phase diagram). The used surfactants 
were Capryol 90, transcutol P, soybean lecithin, or different combination of them.  
 
The ternary phase diagrams were accurately generated using a water titration 
method (50, 51). In this method, oil was mixed carefully with surfactant or surfactants 
mixture in diverse weight ratios from 0.5:9.5 to 9.5:0.5 (%W/W) by vortex for 2 min at 
25°C. Then the produced mixture was slowly titrated with aliquots of MilliQ water until 
the appearance of the first turbidity, which reflected the boundary point that differentiated 
the end of the water-in-oil (W/O) ME region and the beginning of macroemulsion region. 




triangle represents the oil while the other apices represent surfactant/co-surfactant and the 
aqueous phase (73). 
 
Ternary or pseudo-ternary phase diagram that showed the largest ME area was 
selected to pick up one point to prepare the primary W/O ME to be used for further 
investigations. The point that picked up was consisted of 20% water + 30% Labrafac 
lipophile WL1349 + 50% (Capryol 90 & soybean lecithin, 1:1 mixture). 
 
 
Preparation of external aqueous phase and incorporation of the bioadhesive 
polymers 
 
For preparation of the external aqueous phase, several surfactants with high HLB 
values (>12) were screened such as Tween 80, Cremophor® EL (74), poloxamer 188, brij 
97 and Labrasol. Aqueous solutions of different concentrations of these surfactants were 
prepared and tested by titration with the previously prepared primary W/O ME until the 
appearance of the first turbidity.  
 
The surfactant solution that could incorporate the greatest amount of the primary 
W/O ME was selected for further investigations. In order to increase the amount of 
incorporated W/O ME, the selected surfactant was mixed with other surfactants and/or 
co-surfactant. 
 
After surfactants screening, the external aqueous phase was prepared by 
dissolving 7.4% Labrasol, 7.4% Cremophor® EL and 22.2% propylene glycol in distilled 
water (Table 2-1). Based on the results of pregabalin solubility study, only 40% of the 
predetermined pregabalin dose (0.6%, that was selected after a preliminary study) was 
dissolved in the internal aqueous phase of the primary W/O ME and the remaining 60% 
was dissolved in the external aqueous phase. The bioadhesive polymers; chitosan (1.1%), 
sodium alginate (0.4%) or Carbopol 981 (0.15%) was soaked and allowed to swell 
overnight in the previously prepared external aqueous phase (1% acetic acid was used 
instead of water in case of chitosan). 
 
 
Preparation of the final multiple W/O/W ME 
 
For preparation of the final formulation, the previously prepared drug-loaded 
primary W/O ME was incorporated accurately drop wise into the drug-loaded external 
aqueous polymeric solution (75) and gently mixed under magnetic stirring until a clear 






Table 2-1.  Composition of pregabalin-loaded bioadhesive multiple W/O/W ME 
 
Ingredient (%W/W) Chitosan ME Sod. alginate ME Carbopol ME 
Pregabalin 0.6 0.6 0.6 
Labrafac lipophile WL1349 7.8 7.8 7.8 
Capryol 90 6.5 6.5 6.5 
Lecithin 6.5 6.5 6.5 
Labrasol 7.4 7.4 7.4 
Cremophor® EL 7.4 7.4 7.4 
Propylene glycol 22.2 22.2 22.2 
Chitosan 1.1 — — 
Sod. alginate — 0.4 — 








Our constructed ternary and pseudo-ternary phase diagrams 
  
For preparation of stable ME system, the HLB value of the surfactant used during 
the preparation of the W/O ME should be fall in the range of 3-6 while the HLB value of 
the surfactant that required for the O/W ME formation should be in the ange of 8-18 (76). 
In the current work, we followed this rule during the preparation of our multiple ME. For 
the preparation of the primary W/O ME we selected surfactant with low HLB value (≤5) 
such as Capryol 90, lecithin and transcutol P. On the other hand, for preparation of the 
final W/O/W ME, all the used surfactants possessed high HLB values (≥12) such as 
Labrasol, Tween 80, poloxamer 188, brij 97 and Cremophor® EL. 
 
Figure 2-3 illustrated the different constructed ternary and pseudo-ternary phase 
diagrams with the W/O ME shown in the shaded regions. These regions represented all 
the possible combinations of the three ME components—aqueous phase, oil phase and 
surfactant or surfactants mixture—that were capable of forming a transparent primary 
W/O ME. By selecting any point in that region, we determined the percentage of the 
three components that were easily mixed to form a W/O ME. Figure 2-3B was selected 
to pick up one point to prepare our W/O ME as it showed the largest shaded area so it 
gave us a higher number of points for selection. The selected W/O ME point consisted of 
20% water + 30% oil (Labrafac lipophile WL1349) + 50% surfactants mixture (Capryol 
90 & soybean lecithin, 1:1). Two important criteria should be available in the point to be 
selected; the first is its ability to form a stable primary W/O ME. The second criterion is 
to be able to incorporate the highest possible amount of water as an internal phase in 
order to dissolve as much as possible of the required drug dose (0.6% pregabalin).  
 
It has been reported that the hydrocarbon chain length of the oil and the 
surfactant(s) is one of the most important factors that affects the ME region in the 
triphase diagram. Coming to the selected pseudo-ternary phase diagram (Figure 2-3B) in 
our study there was a correlation between the hydrocarbon chain length of—Labrafac oil 
& Capryol 90 & lecithin—and the large W/O ME region. Beginning with the two 
surfactants—Capryol 90 & lecithin—Capryol 90 is a propylene glycol monoester of 
caprylic acid (C8). Such a medium hydrocarbon chain allowed it to be easily inserted 
between the two long hydrocarbon chains of lecithin in order to form a homogenous 
interfacial film at the interface between the Labrafac oil phase and the aqueous phase 
(72). Secondly, our oil phase (Labrafac lipophile WL 1349) is a triglyceride ester of 
caprylic (C8) and capric (C10) acids which possessed nearly the same carbon chain 
length of Capryol 90 that allow more homogenous mixing between our ingredients and 
better emulsification behavior.  
 
Labrafac lipophile WL 1349, as a medium chain triglyceride esters has a higher 
solvent capacity and is less susceptible to oxidation compared to long chain triglycerides 
(77). Also, being an ester of saturated medium chain acids (C8 & C10), our oil phase 






Figure 2-3.  Ternary and pseudo-ternary phase diagrams of the primary W/O ME 
 
The ME was formed of Labrafac oil/water and surfactant or surfactant mixture: 
 (A) Capryol 90, (B) Capryol 90: lecithin [1:1], (C) Capryol 90: lecithin [1:2], (D) 
Capryol 90: lecithin [2:1], (E) Transcutol P and (F) Transcutol P: lecithin (1:1). The black 
colored regions represent the W/O ME area. Figure 2-3B was selected to pick up one 
point to prepare our W/O ME as it showed the largest ME shaded area which gave us a 




Additionally, the shorter the hydrocarbon chain length of the oil the deeper the oil 
penetration into the hydrophobic tails of the surfactant allowing a higher stability of the 
interfacial film leading to the formation of the ME (65). In addition of being compatible 
with Capryol 90, lecithin was selected as a surfactant in our ME because it has the 
advantage of being safe, biocompatible, non-toxic, naturally occurring and well-tolerated 
surfactant (47, 72). Furthermore, it is in many respects regarded as an ideal biological 
surfactant because of its biodegradation (79). Despite of all these advantages lecithin 
possessed undesirable properties that may hinder its use as a surfactant for preparation of 
ME. In fact, it has two opposite characteristics as it has a strong hydrophobicity due to 
the presence of its two long hydrocarbon chains and in the same time it has strong 
lipophobicity due to the presence of hydrated zwitterionic polar groups and a strong 
tendency to form lamellar liquid crystalline phase. This limitation could be overcome by 
combining it with other surfactant in order to decrease its rigidity (72). Capryol 90 
provided our ME system with this advantage and decreased the rigidity of lecithin by 
being incorporated into the interfacial film allowing the formation of ME. 
 
 
The external aqueous phase surfactant/co-surfactant mixture composition 
 
Among all the screened surfactants and co-surfactants, surfactant mixture of 7.4% 
Labrasol and 7.4% Cremophor® EL in the presence of 22.2% propylene glycol as a co-
surfactant (75) was the most efficient external aqueous phase to produce our final 
multiple W/O/W ME (Figure 2-4). This combination of surfactants and co-surfactant 
helped to incorporate the maximum amount of the primary W/O ME (26% w/w) during 
the final emulsification process in order to prepare our final multiple W/O/W ME. 
Regarding the safety of our ME system, several studies previously reported the safety of 
the different surfactants and co-surfactant that have been used in the preparation of our 
formulations at the specific concentrations. Fialho et al used Cremophor® EL at a 
concentration of 15% in their ophthalmic ME formulation of dexamethasone to the eye 
(74). Also, they stated that according to the information provided by the manufacturer, 
Cremophor® EL at a concentration up to 30% does not have any irritant effect on the eye 
(80) (74). Furthermore, solutions of propylene glycol cause no irritations to the rabbit eye 
at a concentration up to 50%, whereas the undiluted propylene glycol only associated 
with a weak conjunctival redness (79, 81, 82). Also, Labrasol as a nonionic surfactant is 
comprised of mixture of mono-, di- and triglycerides and mono- and di-fatty acid esters 
of polyethyleneglycol, with caprylic and capric acids as the predominant fatty acids. 
Thus, Labrasol is compatible with both the oil phase (Labrafac lipophile) and the internal 
hydrophobic surfactant (Capryol 90). 
 
On the other hand, Liu et al reported that Labrasol at a concentration of 5% could 
produce a slight ocular irritation when used as ophthalmic penetration enhancer for their 
drug (baicalin) (83). Despite of using Labrasol as a surfactant in our ME at a 
concentration above the limit that was previously reported, our results showed that it 
didn’t produce any significant ocular irritation. Thus, the excellent ocular tolerability of 
our ME might be due to the demulcent effect of propylene glycol that capable of masking 






Figure 2-4.  Cartoon showing composition of pregabalin-loaded multiple W/O/W 
ME eye drops 
 
Our new developed multiple ME consists of Labrafac lipophile WL1349 as the oil phase, 
MilliQ water as the internal aqueous phase, mixture of Capryol 90 & soybean lecithin, 
1:1 as the hydrophobic surfactant/cosurfactant and mixture of Labrasol and Cremophor® 
EL in the presence of propylene glycol as the external hydrophilic surfactant/ 
cosurfactant. Hence, we have incorporated 40% of the predetermined pregabalin dose in 
the innermost aqueous phase of our developed ME system while incorporating the 








Solubility studies showed that pregabalin solubility in water, 0.01N HCL and 
0.01N NaOH was 37.7±0.16, 41.48±0.30 and 39.28±0.25 mg/ml, respectively. In contrast 
the pregabalin concentration in Labrafac lipophile WL 1349 or the surfactant mixture 
(Capryol 90 & soybean lecithin, 1:1 mixture) was under the detection limit. Water was 
selected to be used as internal aqueous phase because our preliminary study demonstrated 
that there was an incompatibility between the ME components and the acidic or alkaline 
internal aqueous phases. Based on the solubility data we dissolved 40% of the pregabalin 





CHAPTER 3.    IN VITRO CHARACTERIZATION OF THE PREPARED 





Ophthalmic drug delivery via simple solution eye drops are relatively inefficient 
because of the different clearance mechanisms in the eye. Actually, the drug residence 
time and the drug transport through the corneal epithelium are considered the main two 
factors that determine the drug bioavailability after topical instillation of eye drops. 
However, the optimum ocular delivery system should be applied once or twice per day 
without causing irritation or blurred vision and at the same time applied easily as eye 
drops. Currently, MEs are one of the most interesting ocular drug carrier systems that are 
designed to address multiple challenges in the ophthalmic delivery. MEs have been 
reported to achieve a remarkable increase in the residence contact time (85), an 
enhancement in the drug penetration (86) and a controlled sustained release of several 
ophthalmic drugs (50).  
 
Because of the negatively charged corneal epithelium, MEs that include cationic 
surfactants showed an electrostatic interaction with the corneal epithelium that leads to an 
increase in the residence time, which would cause a higher drug concentration in the 
precorneal area and thus a greater improvement in the bioavailability. Also, an increase in 
the residence time of ME ophthalmic formulations could be attributed to the increase in 
the tear film viscosity after ME application. Furthermore, during the ME preparation, a 
polymer can be incorporated in the aqueous phase to increase the mucoadhesion and 
hence the residence time of the applied formulation. Some studies reported the 
effectiveness of the added bioadhesive polymer in controlling the release kinetics from 
ME eye drops. 
 
In this chapter we described how our prepared multiple W/O/W ME formulations 
were evaluated for their droplet size, polydispersity index (PDI), zeta potential, 
morphology, viscosity, bioadhesion, in vitro drug release and corneal permeability. 
Furthermore, we performed immunohistochemistry to determine the expression of 
CACNA2D1—pregabalin target protein— in the Dutch belted rabbit eyes. 
 
 
Materials and Methods 
 
Sodium phosphate dibasic, sodium bicarbonate, potassium chloride, potassium 
dihydrogen phosphate, calcium chloride dihydrate, dipotassium hydrogen phosphate, 
glacial acetic acid, Triton X-100, Cremophore® EL, MTT reagent 
(methylthiazolyldiphenyl- tetrazolium bromide) and glutathione disulfide were purchased 
from Sigma-Aldrich (St. Louis, MO). Propylene glycol, magnesium chloride 
hexahydrate, dextrose, Tween 80, sodium chloride, gastric mucin (type II), dimethyl 
sulfoxide (DMSO) and phosphoric acid were procured from Fisher Scientific (Fair Lawn, 




Regenerated cellulose membrane (molecular weight cut-off 5,000 Da, Harvard  
Apparatus Co., Holliston, MA). Keratinocyte-SFM serum free medium was purchased 
from Life Technologies Corporation (Grand Island, NY). DMEM/F-12 (Dulbecco's 
modified Eagle’s medium/nutrient mixture F-12) was purchased from Mediatech, Inc. (A 
Corning Subsidiary Manassas, VA). Fresh whole eyes of male New Zealand white rabbits 
were procured from Pel-Freez Biologicals (Rogers, AR). 
 
 
Measurement of the pH 
 
The pH values of each ME formulation were measured using a pH meter (Corning 
pH meter 440; Corning Inc., Corning, New York). One gram of each formulation was 
dispersed in 20 mL of MilliQ water then the pH was measured. The experiment was 
repeated three times and the results were presented as mean±SD.  
 
 
Average droplet size, polydispersity index (PDI) and zeta potential measurement 
 
The mean droplet size, PDI and zeta potential (ZP) of our ME formulations were 
determined after suitable dilution using Zetasizer (Nanoseries, nano-ZS, Malvern 
Instruments Limited, UK) (86). All measurements were performed at 25 ± 2°C. The 
results of three independent test runs were presented as mean±SD. 
 
 
Transmission electron microscopy  
 
The morphology of our pregabalin-loaded ME eye drops was examined using 
transmission electron microscopy (TEM) (JEOL JEM1200EX II electron microscope). 
Briefly, the ME formulation was diluted 1:100 with deionized water. Two microliters of 
the diluted ME were placed on 400 mesh copper grids covered with formvar film 
(Electron Microscopy Sciences EMS, Hatfield, PA). The grids were allowed to dry 
overnight in a desiccator before examination by TEM.  
 
 
Determination of the viscosity 
 
A cone (1.5°) and plate rotary viscometer (Brookfield DV-II+ programmable 
viscometer; Brookfield Engineering Laboratories, Middleboro, MA) was used to 
determine the viscosity of our ME disperse system according to our previously published 
protocol (87, 88). Each formulation (500µl) was placed on the stationary plate of the 
viscometer for 5min before each measurement to reach the running temperature (89). The 







Measurement of the bioadhesive force 
 
The bioadhesive force of our ME eye drops was determined by a simple method 
that depends on evaluation of the rheological synergism that happen upon mixing the 
bioadhesive polymer with mucin dispersions (90, 91). Gastric mucin type II (15%, w/v) 
was dispersed in simulated tear fluid (pH 7.4) and allowed to dissolve overnight at 4°C. 
Immediately before measurment,  mucin dispersion was warmed to 35°C and then mixed 
with our prepared ME formulations that had been warmed to the same temperature. Then, 
the viscosities of mucin dispersion, formulations and their mixture were measured in 
triplicate using the Brookfield viscometer. Thus, viscosity change due to bioadhesion as 
well as the bioadhesive forces were calculated employing the following equations 
(Equation 3-1 and Equation 3-2) and the results were represented as mean±SD (90, 91).  
 
ηb = ηt – (ηm + ηp )                                 (Eq. 3-1) 
 
Fb = ηb x γ                                             (Eq. 3-2) 
 
where ηb is the viscosity due to bioadhesion, ηt is the viscosity of the mixture, ηm  is the 
viscosity of mucin dispersion, ηp is the viscosity of the formulations, Fb is the bioadhesive 
force and γ is the shear rate at which the viscosity value was measured. 
 
 
In vitro drug release  
 
Pregabalin release behavior from our ME eye drops was studied according to our 
previously published protocol (89, 92). Briefly, we used 1500μl fast micro-equilibrium 
dialyzers to which a semipermeable regenerated cellulose membrane with molecular 
weight cut-off 5,000 Da was attached (Harvard  Apparatus Co., Holliston, MA). One 
hundred microliters of our ME formulations or the controls were placed in the donor 
chamber. The used control formulations were 0.6% simple pregabalin aqueous solution 
or 0.6% pregabalin viscous solution using different polymers (chitosan, sodium alginate 
and Carbopol 981). Warmed phosphate buffer pH 7.4 (1.5 ml at 35±0.5°C) was placed in 
the receptor chamber. The dialyzer was kept in thermostatically controlled shaker (at 50 
rpm and 35±0.5°C). At predetermined time intervals ranging from 0.25 to 24 h, the entire 
medium in the receptor chamber was withdrawn and replaced immediately by 1.5 ml of 
fresh warmed buffer solution. Sink conditions were maintained at all times. All 
experiments were carried out in triplicate and the concentration of the released drug was 
then determined by HPLC. The cumulative percent amount released of pregabalin was 
calculated as mean±SD.  
 
 
Corneal permeability study 
 
Modified rounded junction Franz diffusion cells (PermeGear Inc) were used to 
measure the pregabalin corneal permeability. Corneas were mounted to the cells with the 




A circulating water bath was used to maintain the temperature of the cells at a 35±0.5°C 
(11, 94). One hundred microliters of pregabalin-loaded ME eye drops—chitosan ME, 
sodium alginate ME and Carbopol 981 ME, in addition to the two controls, pregabalin 
aqueous solution and pregabalin-loaded in Carbopol 981 viscous solution—was placed in 
the donor chamber. The receptor chamber was continuously stirred and was filled with 5 
mL of balanced salt solution enriched with bicarbonate, dextrose, and glutathione (BSS-
PLUS®, Alcon Laboratories Inc., Fort Worth, TX) (11). At predetermined time intervals 
(1, 2, 3, 4, 5 and 6h), 500µL were withdrawn from the receptor chamber and replaced 
with an equal volume of fresh warmed BSS-PLUS®. The drug concentration in 
withdrawn samples was immediately determined by HPLC assay as described above. The 
results were plotted as cumulative amount permeated (µg) versus time. Also, the steady-
state flux (SSF) was calculated by dividing the rate of transport at steady state by the 
surface area of the cornea through which permeation occurred. 
 
Flux (J) as well as permeability coefficient (P) was calculated using the following 
equations (Equation 3-3 and Equation 3-4) (93, 95): 
 
Flux (J) = (dM/dt) /A                                 (Eq. 3-3) 
 
Permeability (P) = Flux/Cd                         (Eq. 3-4) 
 
where, M is the cumulative amount of drug transported, A is the surface area of the 
corneal membrane (0.636 cm2) exposed to the drug and Cd is the initial drug 
concentration in the donor chamber. 
 
The data were statistically analyzed using one-way analysis of variance 
(ANOVA) test followed by Tukey’s multiple comparisons test.  Statistical calculations 






To immunolocalize pregabalin target protein—CACNA2D1—in Dutch belted 
rabbits’ paraffin-embedded eye sections (50 µm thickness), we used our previously 
published methods (96, 97). Briefly, we used 10% goat serum to block non-specific 
binding sites in tissue sections. An anti-CACNA2D1 monoclonal antibody 
(ThermoFisher Scientific, Rockford,USA, catalog # MA3-921; 1:100) was used in our 
study as the primary antibody along with donkey anti-mouse Alexa fluor® 488 secondary 
antibody (Invitrogen, Waltham, MA; catalog #A21202; 1:200) and DAPI (Vector 
Laboratories, Inc., CA; catalog #H-1200) as a nuclear counterstain. Vector® 
TrueVIEW™ Autofluorescence Quenching Kit (Vector Laboratories, Inc., CA; catalog 
#SP-8400) was used to remove the unwanted background autofluorescence in our 
sections. Sections were viewed and images were obtained using a Nikon C1 confocal 








Average droplet size, PDI and zeta potential 
 
 Table 3-1 listed the apparent mean droplet size, PDI and ZP values of the oil 
phase of both blank and medicated diluted ME formulations. The droplet size of all the 
prepared ME formulations either blank or medicated were < 20 nm with PDI values < 
0.38. This minuscule droplet size is very important to ensure high bioavailability. 
Because it greatly helped the transcorneal penetration of our ME formulations as it is well 
known that a droplet size less than 200 nm is required for accepted passive drug targeting 
through biological membranes (98, 99). The obtained small droplet size of our ME was 
an expected outcome because of the presence of propylene glycol as a co-surfactant. As 
this co-surfactant could penetrate the interfacial film formed by the surfactants mixture at 
the oil/water interface, it lowered its viscosity and made it more flexible which in turn 
resulted in the formation of micro-droplets that have a smaller-radius curvature, which 
finally resulted in the production of transparent ME systems (74, 100). In addition, 
Nidhin et al., 2008 reported that PDI values ranges from 0.01 to 0.5 is an indication for a 
narrow size distribution while values higher than 0.7 indicate a very broad distribution 
(101). Similarly, our prepared ME formulations had a narrow droplet size distribution 
(PDI<0.38). 
 
Concerning the zeta potential, both blank and medicated sodium alginate and 
Carbopol MEs possessed large negative charges (> -26mV). On the other hand, both 
blank and medicated chitosan MEs were positively charged. This difference in the type of 
the charge is an inherent property for the used polymer. Whatever its type, the surface 
charge of any colloidal system is very important factor to achieve a long-term stability as 





The TEM image revealed that the microstructure of our ME appeared as a 
homogenously distributed separate single ME droplets with a spherical regular outline 




Viscosity and bioadhesion 
 
Figure 3-2. presents the viscosity and bioadhesion force values of the prepared 
formulations containing 0.6% pregabalin. The tested formulations included; ME 
formulations prepared using three different bioadhesive polymers—chitosan, sodium 
alginate and Carbopol 981—compared to their control formulations that prepared from 
the same polymers at the same concentrations in absence of the ME colloidal system. 





Table 3-1.  Droplet size, PDI and zeta potential of blank and medicated ME formulations 
 
 
Type of ME eye drops 
Mean droplet size (nm)  PDI  Zeta potential (mV) 
Blank Medicated  Blank Medicated  Blank Medicated 
PRG chitosan ME 17.4±0.0 17.4±0.3  0.36±0.0 0.37±0.0  15.9±3.3 10.2±2.3 
PRG sod. alginate ME 16.8±0.3 16.5±0.2  0.34±0.0 0.34±0.0  -26.8±0.8 -26.7±1.7 






Figure 3-1.  TEM image of pregabalin-loaded ME 
 
Our ME appeared as a homogenously distributed separate single ME droplets with a 







Figure 3-2.  Viscosity and bioadhesion of pregabalin-loaded ME formulations and 
controls 
 
The viscosity values in cP (A) and the bioadhesive force in dyne/cm 2 (B) of pregabalin-
loaded ME eye drops as well as the controls were calculated as mean±SD; n=3. 
Formulations contained Carbopol 981 either in the presence or absence of ME system 
have the highest viscosity values compared to those contained chitosan or sodium 
alginate. However, chitosan-including formulations possessed the highest bioadhesion 




have the highest viscosity values compared to those contained chitosan or sodium 
alginate (Figure 3-2A). This difference in the formulation viscosity may be attributed to 
the difference in the concentration, crosslinking and molecular weight of the used 
polymers (102). Regarding the bioadhesion of our formulations, chitosan-including 
formulations possessed the highest bioadhesion force compared to the formulations that 
included the other polymers. Actually, there are several factors that may affect the 
bioadhesive force of the polymer including; the ability of the polymer to swell, the extent 
of swelling, the polymer chain flexibility and the type of binding with mucin (103). Thus, 
this high bioadhesive force of chitosan might be attributed to its ability to interact with 
mucin via three different types of interaction—H-bonding, hydrophobic association and 
electrostatic binding due to its carried positive charge—which allowed it to strongly bind 
to mucin compared to sodium alginate and Carbopol which bound only with H- bonding 
(104). Also, the used chitosan possessed high chain flexibility due to its moderate degree 
of acetylation (15-25%), which allowed it to adequately interact with mucin and resulted 
in a higher bioadhesive force (105, 106). Meanwhile Figure 3-2B showed that our 
pregabalin ME formulations have significantly higher bioadhesive force compared to the 
corresponding control formulations (p<0.0001, p<0.01 and p<0.05 for chitosan, Carbopol 
and sodium alginate respectively). The improved bioadhesion of our ME formulations 
might be attributed to the presence of non-ionic surfactants which improved the 
polymers’ chains wetting and swelling and promoted their interaction with mucin which 
resulted in better bioadhesion (103). These results indicated that our ME pregabalin eye 
drops would be expected to have a longer corneal contact time and longer duration of 
action after application into the eye.  
 
 
In vitro release 
 
In vitro release profiles of pregabalin-loaded ME formulations as well as their 
control formulations—pregabalin aqueous solution and pregabalin-loaded in different 
bioadhesive polymers viscous solutions; chitosan, sodium alginate or Carbopol 981—are 
shown in Figure 3-3. Despite being water-soluble drug that characterized by a fast 
release behavior, our ME formulations succeeded to slow and sustain the release of 
pregabalin up to 24h in contrast to the control formulations that exhibited rapid release of 
all the drug loaded in the first few hours. 
 
 Figure 3-3 illustrated that all ME formulations showed an initial fast release 
(≈25% in the first 0.5h) followed by a controlled release for the next 24h. Actually, this 
release behavior was expected and it was considered as a normal outcome for the special 
engineering of our multiple W/O/W ME formulation. Being a multiple ME where small 
pregabalin-loaded water droplets were entrapped within larger oil droplets that in turn 
were dispersed into an external pregabalin-loaded aqueous phase. Thus, our ME unique 
structure could govern the drug distribution inside the formulation. Only 40% of the drug 
dose was located in the innermost layer of the ME while the remaining 60% was 
incorporated in the external polymeric outermost aqueous layer. However, the initial fast 
release might be due to the presence of this 60% of the drug dose in the external aqueous 






Figure 3-3.  Cumulative amount released (%) of pregabalin from ME eye drops 
 
Data are expressed as mean±SD; n=3. 
Our ME formulations succeeded to slow and sustain the release of pregabalin up to 24h 
in contrast to the control formulations that exhibited rapid release of all the drug loaded 




after simple diffusion through the viscous polymeric external aqueous layer. On the other 
hand, the presence of 40% of the drug dose in the innermost aqueous layer. of the ME 
was responsible for the controlled release behavior that lasted up to 24h. The drug was 
located in the innermost aqueous layer, which was surrounded by an intermediate layer of 
oil. Therefore to be released, pregabalin must pass through two interfaces⎯the inner 
W/O interface and the outer O/W interface⎯after which it has to diffuse through the 
viscous bioadhesive polymer in the external aqueous layer. Also, since our drug is water-
soluble and its solubility in oil is negligible, the presence of the oil layer might control its 
release and greatly prolong the time required for it. Because of this structure, the time 
required for the drug to pass through all these stages was greatly prolonged.  
 
One more reason for this slow release was the presence of the drug in both 
innermost and outermost layers of our ME system. The presence of the drug in the 
external layer might hinder or slow the drug release from the innermost layer by affecting 
the drug concentration gradient across the intermediate oil layer of our ME and resulted 
in an overall slow release behavior (107). Moreover, the bioadhesive polymer ensured 
that the formulation would remain on the corneal surface for enough time to allow the 
sustained release of the drug. Finally, we could conclude that this specially designed 
release behavior was intended in order to produce a rapid onset with a longer duration of 
action upon instillation into the eye. 
 
Comparing the rate of pregabalin release from the ME formulations and their 
controls, we found that all formulations could be arranged in the order of; pregabalin in 
water > pregabalin in polymeric viscous solution > pregabalin ME. This arrangement 
may be due to the free water solubility of pregabalin. When the drug being in aqueous 
solution, no more steps were required to be ready for corneal transport while one more 
diffusion step was added when being in viscous polymeric solution. On the other hand, 
several steps were required as previously mentioned when being in ME form.  
 
The drug release profiles from these systems indicated two different release 
mechanisms at different stage of release: a large initial burst release followed by a slow 
release in the long time. The burst drug release was controlled by diffusion through the  
viscous polymeric external aqueous layer while the sustained time release was controlled 





In order to determine the drug transcorneal permeability from our ME 
formulations as well as from the two controls—pregabalin aqueous solution and 
pregabalin viscous polymeric solution—we used fresh rabbit corneas excised from the 
whole eyes of New Zealand white rabbits that shipped overnight from Pel-Freez 
Biologicals in Hanks balanced salt solution over wet ice. In order to keep the cornea alive 
during the whole experiment (6h) we used BSS-PLUS® irrigating solution as a receptor 
medium. This solution has a similar composition to aqueous humor and commonly used 




physiologic integrity of intraocular tissues (108, 109). As previously mentioned, 
pregabalin is a BCS class I drug, which suffers from a rapid absorption that leads to short 
duration of action. Actually, this process was against the required sustained release 
behavior. Therefore the availability of an appropriate drug delivery system that could 
maintain the high drug permeability and prolongs its corneal contact time is an urgent 
need. In the current study we succeeded to achieve this goal by incorporating pregabalin 
in our ME formulations.  
 
 Data shown in Table 3-2 demonstrated that our ME formulation could maintain 
the high permeability associated with pregabalin with no significant difference in the 
permeation rates (dM/dt) Figure 3-4., flux values (J) Figure 3-5. and permeability 
coefficients (P) compared to the used controls (Overall P=0.4191). Furthermore, these 
results presented that the addition of a bioadhesive polymer (Carbopol 981) into an 
aqueous solution of pregabalin had no significant effect on the drug permeability. 
Similarly, Chen et al., 2007 reported that the addition of 0.75% carbomer 940 had no 
significant effect on the permeation rate of triptolide from ME (75). In addition to 
maintaining the high permeability of the drug, our ME formulations were capable of 
prolonging its corneal contact time and sustaining its release that resulted in improving its 
overall bioavailability. These results confirmed the previously obtained in vitro release 






 Immunohistochemistry was performed to determine if pregabalin-target protein, 
CACNA2D1 is expressed in eye tissues of Dutch belted rabbits that are associated with 
IOP modulation before testing the in vivo efficacy of our pregabalin-loaded eye drops in 
these animals. Figure 3-6. illustrated that CACNA2D1 was highly expressed in both the 
ciliary body (non-pigmented epithelium) and the trabecular meshwork where the aqueous 
humor production and drainge occurs respectively. Thus the mechanism through which 
pregabalin decrease the IOP might be through decreasing the aqueous humor production 
by the ciliary body or increasing its drainge through the trabecular meshwork or by both 
mechanisms. Interestingly the IHC results of Dutch belted rabbits are similar to what we 





Table 3-2.  In vitro transcorneal permeability parameters of pregabalin from 












coefficient (P) x10-4 
(cm/s) 
PRG in water 0.285±0.1 0.45±0.13 7.5±2.2 
PRG in Carbopol 0.374±0.15 0.59±0.24 9.8±3.9 
PRG chitosan ME 0.233±0.06 0.37±0.10 6.1±1.7 
PRG sod. alginate ME 0.287±0.18 0.45±0.28 7.5±4.7 
PRG Carbopol ME 0.288±0.08 0.45±0.13 7.6±2.2 
 
Data are expressed as mean±SD; n=6 







Figure 3-4.  Cumulative amount permeated of pregabalin from ME eye drops 
using rabbit cornea 
 
Data are expressed as mean±SD; n=6 
There was no significant difference (Overall P value=0.4191) between the cumulative 
amount permeated from our ME formulations and both the aqueous pregabalin solution 








Figure 3-5.  Transcorneal flux of pregabalin from pregabalin-loaded ME eye 
drops 
 
Data are expressed as mean±SD; n=6 
There was no significant difference (overall p=0.4191) between the transcorneal flux of 








Figure 3-6.  Cellular localization of CACNA2D1 in Dutch belted rabbits eye 
 
A-C” sections from Dutch belted rabbits iridocorneal angle were labeled with anti-
CACNA2D1 antibodies. Pregabalin target protein— CACNA2D1 (green)—is localized 
in the trabecular meshwork (B) and the ciliary body (C). Blue nuclei, TM trabecular 




CHAPTER 4.    DETERMINATION OF SAFETY, IN VIVO EFFICACY AND 
THE CELL TOXICITY OF THE MICROEMULSION EYE DROPS 
 
 
Our previously published data show that pregabalin hydroxypropylmethylcelluse 
(HPMC) viscous eye drops could maintain the IOP-lowering ability of the drug for up to 
6h without causing any irritation either for mice or Dutch belted rabbits eyes (Figure 4-1) 
(24). In contrast, we measured a sustained in vitro release behavior of pregabalin from 
our multiple W/O/W microemulsion eye drops that lasts for 24h. Because we will use the 
same drug in a different formulation, we want to make sure that our formulations 
ingredients are safe to a corneal epithelial cell line and will not harm the eye of the 
experimental animal. These data together suggest that our formulation will be safe to a 
corneal epithelial cell line. Also, it will demonstrate an IOP-lowering ability of the drug 
that may last for more than 24h. To determine the IOP-lowering ability and the mildness 
of our formulations, we will use Dutch belted rabbits.  
 
The aim of the work in this chapter is to determine the safety and the efficacy 
(time and extent) of our developed ME eye drops after a single dose application in Dutch 
belted rabbits. Also, to measure the in vitro cytotoxicity of our formulations by the MTT 








Dutch belted male rabbits (2-2.5Kg) procured from Robinson Services 
(Mocksville, NC) were used to test the IOP-lowering effects of our pregabalin-loaded 
ME formulations. All procedures including rabbits were approved by the Animal Care 
and Use review board of the University of Tennessee Health Science Center (UTHSC) 
and followed the Association of Research in Vision and Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research in addition to the 
guidelines for laboratory animal experiments (Institute of Laboratory Animal Resources, 
Public Health Service Policy on Humane Care and Use of Laboratory Animals).  
 
 
In vivo evaluation of our formulation safety 
 
The safety of our developed multiple W/O/W ME eye drops was tested by 
installation of 100μl of the medicated formulation in the lower conjunctival sac of the 
right eye of Dutch belted rabbits (n=3) while the left eye served as a control. Eyes were 
examined every hour for any sign of irritation such as redness, tearing and conjunctival or 
corneal swelling. Slit-lamp examination was performed for all rabbits eyes at the end of 







Figure 4-1.  IOP reduction (%) after application of pregabalin simple eye drops 
 
Pregabalin, a specific modulator of CACNA2D1, lowered IOP in B6 mice in a dose-
dependent manner (A). We measured a dose-dependent reduction in IOP compared to 
control treatment after a single application of ophthalmic formulation containing a range 
of concentrations of pregabalin from 0.3 to 1.2%. The minimal concentration required to 
produce the maximum reduction in IOP was 0.9% (mean ± SEM; n = 6). Pregabalin-
induced IOP reduction is haplotype-specific. Mice carrying the B parental allele of 
Cacna2d1 (i.e., B6 and BXD14) are more responsive to pregabalin (0.9%) than mice 
carrying the D parental allele (i.e., D2 and BXD48; mean ± SEM; n = 4–6). A single dose 
of pregabalin eye drops (0.9%) lowers IOP by 22.1% in Dutch belted rabbits (n = 5) (C). 
Reprinted with permission. Chintalapudi SR, Maria D, Di Wang X, Bailey JNC, 
consortium N, International Glaucoma Genetics c, et al. Systems genetics identifies a role 
for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility. Nat 




In vivo evaluation of our formulation efficacy  
 
The IOP-lowering effect of our multiple ME formulations was determined using 
Dutch belted rabbits (n=3) (111). During the study one hundred microliters of the ME eye 
drops were applied into the inferior conjunctival sac of the right eye of the Dutch belted 
rabbits while the left eye served as a control by receiving 100μl of the blank ME 
formulation. The IOP was measured using a Tono-pen AVIA (Reichert Technologies, 
Depew, NY) immediately before the application of the formulation (baseline) and at 
predetermined time intervals until it returned back to its baseline value (24, 112). Five 
consecutive IOP readings were averaged for each individual eye at each measurement.  
 
Evaluation of pregabalin formulations was based on comparing the calculated 
pharmacodynamic parameters including; maximum percent reduction in IOP [IOP 
reduction (%)], the time required to reach maximum decrease in IOP (Tmax), the time 
required for IOP to return again to its baseline (i.e., end of drug effect; Tend) and the total 
area under the IOP reduction (%)-versus-time curve (AUCtotal). All results were 
expressed as mean±SEM.  
 
 
In vitro evaluation of formulation cell toxicity 
 
In vitro cytotoxicity of our pregabalin-loaded Carbopol ME eye drops (this 
formulation was selected based on the obtained in vivo results) was evaluated by the 
methylthiazolyldiphenyl tetrazolium bromide assay using a modified previously 
published protocol (113, 114). MTT assay is based on the ability of healthy cells 
(mitochondria) to reduce the MTT reagent into purple formazan crystals(115).The 
viability assay was carried out in 96-well plates (Costar 3596, Corning Inc., Corning, 
NY). Human corneal limbal epithelial cells (HCLE) (116)was seeded at a concentration 
of 18,000 cell/well and incubated in a humidified environment at 37°C in 5% CO2 for 
24h in Gibco-Keratinocyte-SFM medium (1X) (supplemented with bovine pituitary 
extract, epidermal growth factor and CaCl2.2H2O). After 24h, the medium was replaced 
by 50 μl of artificial tears, then 150 μl of the diluted formulation (2.15μl 
formulation + 147.85μl medium) were added slowly above the artificial tears. This 
dilution was based on the surface area of the cell layer in the well exposed to the 
formulation compared to the actual rabbit corneal surface area. In addition, after different 
time points of incubation (1,2,3 and 6h), the formulation was removed and the plate was 
washed with the culture medium to remove all the traces of the formulation. Two 
hundred microliters of MTT reagent (1 mg/ml in culture medium) was added to each well 
and the plates were incubated at 37 °C for 4h. After incubation the MTT was removed 
and 200μl DMSO was added to each well to dissolve the formazan crystals. The plate 
was then shaken for 15min. The absorbance of the solution was measured at 570nm and 
converted to percent cell viability relative to the control (untreated cells) by a µ-Quant 
universal microplate spectrophotometer (Bio-Tek Instruments, Inc. Winooski, VT). 
Statistical analysis of the percent cell viability data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparisons test. Each experiment was 







In vivo safety and efficacy 
 
Our recently published data showed that pregabalin (0.9% in 2% HPMC viscous 
eye drops) has the ability to decrease IOP in both mice (28.6±3.5%) and Dutch belted 
rabbits (22.1±2.8%) while the IOP returned back to baseline after only 6h (Figure 4-1) 
(24). Thus, based on these results we sought to determine if our new sustained release 
glaucoma eye drops could maintain the IOP at lower level for longer period of time after 
a single drop application using Dutch belted rabbits. Figure 4-2 illustrated the percent 
IOP reduction after application of 0.6% pregabalin ME eye drops and Table 4-1 listed all 
the calculated pharmacodynamic parameters.  
 
Among all the tested ME formulations, pregabalin Carbopol ME provided the 
maximum IOP-lowering effect (42.3±2.6% reduction in IOP) that returned to baseline 
at 32.7±1.3h after application (AUC =169.9±13.4 mmHg.h) compared to the control 
formulation (pregabalin in Carbopol in absence of ME), which produced only a 
29.4±1.4% IOP reduction that returned to baseline at 9.3±0.7h (AUC=39±4 mmHg.h). 
Regardless the type of polymer, all our prepared ME formulations induced an IOP % 
reduction > 34% (Table 4-1).  
 
Statistical analysis of different pharmacodynamic parameters (Table 4-2) showed 
that there was no significant difference either in percent IOP reduction or Tmax values 
between all the tested formulation including control (P=0.2504 and 0.9567, respectively). 
This non-significant difference between all the tested formulations might be due to the 
presence of free drug that was available to produce a rapid onset that reached its 
maximum after 3h. On the other hand, the Tend values of our ME eye drops were 
significantly longer compared to the control formulation (p<0.0001). This might be due 
to the ability of our ME formulations to sustain pregabalin release and prolong its corneal 
contract time. 
 
The IOP-lowering results of our ME formulations proved that we have succeeded 
to achieve our goal to produce bioadhesive formulations with rapid onset and long 
duration of action. The main cause of the rapid onset was the presence of 60% of the drug 
dose in the external aqueous phase of the ME while the presence of the remaining 40% in 
the innermost aqueous layer was responsible for the long duration of action that lasted for 
32.7±1.3h for the Carbopol ME. Upon comparing the IOP-lowering effects of the 
three tested ME, it was found that they could be arranged as follow; Carbopol ME > 
sodium alginate ME > chitosan ME. The main cause of this arrangement might be 
the difference in their viscosities (Figure 3-2A). The high viscosity of Carbopol ME 
and its in situ gelling ability at the physiological pH (117) prevented its drainage 
outside the eye and allowed enough time for the bioadhesion interaction to occur. In 
addition, the slow release rate together with the high viscosity and bioadhesion 
allowed for the longer duration of action. Although chitosan ME has the highest 






Figure 4-2.  IOP reduction (%) after 0.6% pregabalin ME eye drops application in 
Dutch belted rabbits 
 
Data are expressed as mean±SD; n=3. 
Pregabalin-loaded Carbopol ME eye drops provided the maximum IOP-lowering effect 
(42.3±2.6% reduction in IOP) that returned to baseline at 32.7±1.3h after application 
(AUC =169.9±13.4 mmHg.h) compared to the control formulation (pregabalin in 
Carbopol in absence of ME system), which produced only a 29.4±1.4% IOP reduction 




Table 4-1.  Pharmacodynamic parameters after application of 0.6% pregabalin-
loaded ME chitosan, sod. alginate, Carbopol 981 and control eye drops to Dutch 
















Baseline IOP 21.2±0.4 20.9±0.2 21.4±0.7 22.1±0.4 
IOP at Tmax 13.9±1.0 13.6±0.2 12.3±0.5 15.7±0.4 
∆IOP -7.3±1.3 -7.3±0.4 -9.1±0.8 -6.5±0.4 
% Reduction in IOP  34.1±5.4 35.0±1.7 42.3±2.6 29.4±1.4 
Tmax (h) 4.0±1.0 3.7±0.3 3.3±0.9 3.3±1.5 
Tend (h) 20.0±0.0 24.0±0.0 32.7±1.3 9.3±0.7 
AUC total (mmHg. h) 69.5±14.2 80.7±4.6 169.9±13.4 39.0±4.0 
 
Data are expressed as mean±SEM; n=3 
Tmax (h), time to maximum response in hours;  
Tend (h), time to end of response in hours;  





























% Reduction in IOP  0.2504 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
Tmax (h) 0.9567 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
Tend (h) <0.0001 <0.001 <0.0001 <0.0001 <0.05 <0.0001 <0.0001 
AUC total (%. h) 0.0001 <0.01 <0.001 <0.0001 >0.05 >0.05 >0.05 
 
CTL: control 
Overall p value represents the outcome of the one-way ANOVA analysis.  





capacity among our tested ME formulations (Tend and AUCtotal) (Table 4-1). This 
might be due to its low viscosity that led to the drainage of some of the formulation 
outside the eye before being strongly adhered to the eye surface. 
 
Although both pregabalin-loaded Carbopol ME and the control formulation 
contained Carbopol 981 as a polymer at the same concentration, the ME possessed 
better IOP-lowering capacity and longer duration of action (Figure 4-2 and Table 4-
1). This might be due to the higher bioadhesive force of the ME formulation due to 
its content of non-ionic surfactants that have the ability to improve the polymer chain 
wetting and swelling and so promoted its interaction with the mucin layer that 
covered the eye surface and so resulted in stronger bioadhesion and longer duration 
of action (103). 
 
Similarly, Naveh et al., (118) reported that emulsion-based pilocarpine eye 
drops might be used as a once-daily therapy for glaucoma compared to several daily 
applications of generic pilocarpine simple eye drops. However, they presented that a 
single dose of pilocarpine emulsion eye drops induced a great reduction in IOP of 
normotensive rabbits compared to the generic eye drops (28.5 % and 18%, 
respectively), they encouraged further studies to be done to determine the mechanism 
through which emulsion eye drops produced this marked reduction of IOP with a 
long duration of action. 
  
Regarding the safety of our ME eye drops, the slit-lamp biomicroscopic 
examination that performed after the IOP of Dutch belted rabbits returned back to 
baseline in the IOP in vivo study showed that there was no sign of irritation such as 
redness or swelling. In addition, cornea was clear with normal smooth epithelial surface, 
no flare in aqueous humor and lens was clear (Figure 4-3). 
 
 
In vitro cytotoxicity 
 
 The results of in vitro cytotoxicity assay of our pregabalin-loaded Carbopol ME 
and both negative and positive controls at different time points (1,2,3 and 6h) are 
illustrated in Figure 4-4. The obtained results showed that the cell viability of our tested 
formulation was significantly different from that of the positive control (1% Triton-X 
100) at all the time points (p< 0.0001). Upon comparing the cell viability of the tested 
formulation with that of the negative control (untreated cells), it was found that there was 
no significant difference at all the different tested time points (p>0.9), which indicated 
that pregabalin as a drug and both Carbopol and our multiple ME system have no 
cytotoxicity to HCLE cell line. Furthermore, the time of incubation of our formulation 
with the HCLE cells was a very important parameter during the cytotoxicity assay. 
Because we thought to consider the strong bioadhesion and the long contact time of our 
ME formulation, we determined the cell viability after 1, 2, 3 and 6 h of incubation. 
Similarly, Andres-Guerrero et al., (116) studied the cytotoxicity of their new formulation 
of Timolol maleate that contained bioadhesive polymers as well as the traditional Timolol 






Figure 4-3.  Slit lamp examination after application of pregabalin-loaded ME eye 
drops 
 
Cornea and lens were clear with no signs of irritation after application of a single dose of 
our developed ME eye drops—chitosan ME, sodium alginate ME and Carbopol ME— in 






Figure 4-4.  Cytotoxicity histogram of pregabalin-loaded Carbopol ME eye drops 
using HCLE 
 
Data are expressed as mean±SD; n=8. 
Pregabalin as a drug and both Carbopol and our multiple ME system have no cytotoxicity 





that as their formulation had a bioadhesive polymers that would increase the contact time 
of their formulations on the eye surface, so to stimulate a long-term therapy they did the 
assay for longer period of time (1 and 4 hours). 
 
However, 15 minutes of incubation is sufficient for testing the cell toxicity of 
conventional topical ocular formulations which supposed to be eliminated from the eye 




CHAPTER 5.    STABILITY STUDY OF PREGABALIN-LOADED CARBOPOL 





The main purpose of the stability testing of a pharmaceutical drug product is to 
establish its shelf life and the different recommended storage conditions. Hence, the drug 
product should be exposed to a variety of environmental conditions for a specific time 
including temperature, humidity and light. To be able to study the stability of a new drug 
substance or a new drug product the International Conference on Harmonisation of 
technical requirements for registration of pharmaceuticals for human use (ICH) stated a 
specific guidance that defined the stability data package required for a registration 
application in the United States, the European Union and Japan. According to the ICH 
guidelines the new tested drug product should be packaged in a container closure system 
that is the same or imitates the actual packaging for storage and distribution. Also, at least 
three batches of the pharmaceutical product are required to conduct the stability study 
(119). 
 
For long-term stability study the testing frequency should be at least every three 
months during the first year, every six months for the second year then annually. 
However, a minimum of three time points including the initial and the final time points is 
required for a six-month accelerated stability study. If a significant change in the 
measured parameters observed during the stability study, adding more testing time points 
is highly recommended (119). 
 
Based on the results that we got from our in vivo experiments, among all the 
tested pregabalin ME eye drops; pregabalin-loaded Carbopol 981 ME formulation was 
selected for conducting a variety of stability study tests. 
 
The aim of the work in this chapter was to investigate the physical and the 
chemical stability of our prepared pregabalin-loaded Carbopol 981 ME eye drops. Long-
term stability study was conducted at two temperatures—5°C ± 3°C and 25°C ± 2°C—for 
a period of four months. Nevertheless, accelerated stability study was conducted at 40°C 
± 2°C while intermediate stability study was conducted at 30°C ± 2°C (75) for a period of 
four months. During the stability study the measured parameters were including; pH, 
drug content, droplet size, polydispersity index (PDI), zeta potential as well as the in vitro 
release of our prepared ophthalmic formulation. To study the stability of our pregabalin-
loaded Carbopol 981 ME eye drops, three batches were prepared exactly by the same 











Three samples from the prepared three batches of pregabalin-loaded Carbopol 981 
ME eye drops were submitted to freeze-thaw cycles (-20 to 25°C) of 48 h for 





We also thought to investigate the physical stability of our ME disperse system by 
the centrifuge test(75). Three samples from three different batches of our prepared 
ophthalmic formulation were submitted to centrifugation at different forces of 40.10 g, 
80.20 g, 160.40 g, 320.80 and 481.20 (5.000, 10.000, 20.000, 40.000, 50.000 and 60.000 
rpm) for 30 min using laboratory centrifuge (SORVALL, WX Ultra Series Centrifuge, 






To study the chemical stability of our ME eye drops we thought to follow the 
guidelines established by the ICH. These guidelines stated that if the drug product is 
intended to be stored in a refrigerator the long-term stability study should be assessed at 
5°C ± 3°C for 12 months while the accelerated stability study should be conducted at 
25°C ± 2°C for also 12 months. In addition, the ICH guidelines stated that there is a 
general case that should be applied for the drug product storage conditions when there is 
no specific temperature established for storage.  
 
In the general case the long-term stability study should be conducted at 25°C ± 
2°C while the accelerated stability study should be conducted at 40°C ± 2°C. Also, in the 
general case there is an intermediate stability study that should be conducted at 30°C ± 
2°C.  
 
In our stability study our prepared pregabalin-loaded ME eye drops were filled in 
a white dropper bottles under aseptic conditions then stored in thermostatically controlled 
air ovens at 25°C ± 2°C (121), 30°C ± 2°C and 40°C ± 2°C and ambient humidity for 
four months. Also, our formulations were stored in a refrigerator at 5°C ± 3°C for four 
months. In addition, to easily monitor any change in the physical appearance of our ME 
eye drops, our formulation was filled in a transparent glass bottles (7ml) at each studied 
temperature. The tested formulation was evaluated initially and at specified time intervals 





pH of the prepared multiple ME formulation 
 
Five hundred milligrams of our ophthalmic formulation were dispersed in 10 ml 
of deionized water, then, the pH value was determined using pH meter. 
 
 
Drug content of the prepared multiple ME formulation 
 
To determine the drug content of our ME formulation one hundred milligrams  
was accurately weighed in a stoppered volumetric 10 ml measuring flask. Three 
milliliters of deionized water were added and flask was shaken for 10 mins, then 7 ml of 
absolute ethyl alcohol was added and flask was shaken for additional 10 mins, then 
brought to volume (10 ml) with ethanol and the contents of the flask were mixed well. 
The solution was filtered using 0.22 μm membrane filters (Millipore, Billerica MA) and 
assayed for the total pregabalin content by HPLC, using the method described in chapter 
2. The drug content determination was carried out in triplicate.  
 
 
Average droplet size, PDI and zeta potential 
 
To measure the mean droplet size, PDI and zeta potential of our ME eye drops 
Zetasizer was used after suitable dilution of our formulation as previously mentioned in 




In vitro release 
 
To determine if the sustained release pattern of pregabalin from our developed 
multiple W/O/W microemulsion eye drops changes with time under the different storage 
temperatures, the in vitro release was performed initially and at different time points 
(1,2,3 and 4 months) under the different storage temperatures, we used 1500μl fast micro-
equilibrium dialyzers and followed exactly the same procedure in chapter 3. 
 
The data were statistically analyzed using one-way analysis of variance 
(ANOVA) test followed by Dunnett’s multiple comparisons test.  Statistical calculations 












Our prepared pregabalin-loaded Carbopol 981 ME disperse system submitted to 
both freeze-thaw cycles and centrifugation were observed to be physically stable without 
any sign of creaming, turbidity, phase separation or precipitation. Also, in a period of 4 
months of the stability study at 5°C, 25°C, 30°C and 40°C, no signs of physical 
instability were observed except a slight yellow color of the formulation at 40°C after 
four months which confirmed the high stability of our developed ME eye drops 
specifically at 5°C, 25°C, 30°C.  
 
 
pH of our multiple ME eye drops 
 
Our developed pregabalin-loaded Carbopol 981 ME eye drops had a pH value of 
5.32± 0.21 at the beginning of the stability study while reached a maximum value of 
5.43± 0.15 at 5°C and a minimum value of 4.84± 0.07 at 40°C after four months. Figure 
5-1 and Table 5-1 presented the obtained results at the different time points of the 
stability study (1,2,3 and 4 months) at the four different studied temperatures (5°C, 25°C, 
30°C and 40°C). There was no significant change on the pH value during the test period 
(four month) except at 40°C (p<0.01) (Table 5-2). The obtained results of pH values 




Average droplet size, polydispersity index (PDI) and zeta potential 
 
Figure 5-2 and Table 5-3 showed the results of the mean droplet size at different 
time points of the stability tests at four different temperatures. The initial average droplet 
size of our ME eye drops was 15.58±0.09 while the highest measured value of the droplet 
size after four months of stability study was17.14±0.82. After one month, there was no 
significant alteration in the measured droplet size (p>0.05) (Table 5-4). However, there 
was a significant change after two months (p<0.05) at only 40°C and after three months 
at both 30°C (p<0.05) and 40°C (p<0.01). In addition, after four month of stability study 
there was no significant change in the average droplet size at both 25°C and 30°C 
(p>0.05) while there was a significant change at both 5°C (p<0.05) and 40°C (p<0.05). 
Overall our ME eye drops have a high stability because it maintained its small droplet 
size after a four-month of stability study at all the different studied temperatures. Also, it 
has been reported that ME with smaller droplet size are considered to be more stable than 
those with larger droplets (59).  
 
Figure 5-3 and Table 5-5 presented the results of the PDI during the stability 






Figure 5-1.  The pH of pregabalin-loaded Carbopol ME eye drops at different 
temperatures after four month of stability study 
 
Data are expressed as mean±SD; n=3. 
There was no significant change (p>0.05) on the pH values during the different test 




Table 5-1.  The pH values of our developed pregabalin-loaded ME eye drops at 





5°C 25°C 30°C 40°C 
0 5.32±0.21 5.32±0.21 5.32±0.21 5.32±0.21 
1 5.40±0.07 5.41±0.04 5.31±0.04 5.37±0.05 
2 5.42±0.23 5.21±0.17 5.33±0.10 5.16±0.03 
3 5.39±0.16 5.31±0.13 5.30±0.07 5.10±0.08 





Table 5-2.  Statistical comparisons among pH values of pregabalin-loaded 
Carbopol ME eye drops stored at four different temperatures and the initial pH 





1 month 2 month 3 month 4 month 
5°C 0.7465 0.8608 0.9211 0.6242 
25°C 0.6709 0.8199 0.9999 0.4597 
30°C 0.9999 0.9998 0.9997 0.3701 
40°C 0.8990 0.6002 0.2380 0.0022 
 
P-value represents the outcome of Dunnett’s multiple comparisons tests where we 
compare the pH values at each temperature with the initial pH values after the one-way 
ANOVA analysis. 






Figure 5-2.  The mean droplet size of pregabalin-loaded ME eye drops at different 
temperatures after four month of stability study 
 
Data are expressed as mean±SD; n=3. 
The initial average droplet size of our ME eye drops was 15.58±0.09 while the highest 
measured value of the droplet size after four months of stability study was17.14±0.82. 
Hence our ME eye drops has a high stability because it maintained its small droplet size 




Table 5-3.  The average droplet size of our prepared pregabalin-loaded ME eye 




Droplet size (nm) 
5°C 25°C 30°C 40°C 
0 15.58±0.09 15.58±0.09 15.58±0.09 15.58±0.09 
1 15.52±0.07 15.64±0.27 15.25±0.17 15.31±0.07 
2 16.08±0.64 16.45±0.11 16.51±0.39 17.14±0.82 
3 15.95±0.11 15.94±0.27 16.57±0.73 16.81±0.16 





Table 5-4.  Statistical comparisons among droplet size values of pregabalin-
loaded Carbopol ME eye drops stored at four different temperatures and the initial 
droplet size value of the same formulation 
 
 P-value 
Temperature 1 month 2 months 3 months 4 months 
5°C 0.9622 0.5824 0.5681 0.0151 
25°C 0.9761 0.1644 0.5869 0.1188 
30°C 0.0703 0.1358 0.0234 0.1804 
40°C 0.1663 0.0111 0.0064 0.0270 
 







Figure 5-3.  The PDI of pregabalin-loaded Carbopol ME eye drops at different 
temperatures after four month of stability study 
 
Data are expressed as mean±SD; n=3. 
No significant difference (p>0.05) was observed in the PDI at the four studied 
temperatures at all the time points. Such low PDI suggested that our ME formulation was 
uniform because a lower PDI value meant a higher homogeneous distribution and a 





Table 5-5. The average polydispersity index of our prepared pregabalin-loaded 





5°C 25°C 30°C 40°C 
0 0.256±0.01 0.256±0.01 0.256±0.01 0.256±0.01 
1 0.248±0.00 0.255±0.01 0.249±0.00 0.249±0.00 
2 0.262±0.02 0.261±0.01 0.259±0.00 0.288±0.06 
3 0.262±0.00 0.260±0.01 0.286±0.05 0.263±0.00 





was observed at 40°C (0.288±0.06) compared to the initial PDI value (0.256±0.01). No 
significant difference (p>0.05) (Table 5-6) was observed in the PDI at the four studied 
temperatures at all the time points. Such low PDI suggested that our ME formulation was 
uniform because a lower PDI value meant a higher homogeneous distribution and a 
highly stable ME (59). 
 
 Figure 5-4 and Table 5-7 illustrated the obtained results of the stability study zeta 
potential at different time points. After four months of stability study the highest 
measured negative zeta potential was observed at 40°C (48.36±0.40) compared to the 
initial zeta potential value (31.42±1.14). After one month, there was no significant 
change in the measured zeta potential (p>0.05) (Table 5-8). However, there was a 
significant change after two months at both 30°C (p<0.001) and 40°C (p<0.001). There 
was no significant change after three months at 5°C (p>0.05), while there was a 
significant alteration at the other three studied temperatures (p<0.001). Furthermore, after 
four month of stability study there was no significant change in the zeta potential at 5°C, 
25°C and 30°C (p>0.05), while there was a significant change at only 40°C (p<0.05). In 
general, for any colloidal system the surface charge of very important factor to achieve a 
long-term stability as it resulted in repulsion between droplets and prevented their 
coalescence upon standing. Meanwhile the higher the surface charge the higher the 





 Table 5-9. presented the results of the drug content as pregabalin-percentage 
amount remained in the prepared ME eye drops after storage at different temperatures for 
four months. After one and two month of stability study, there was no significant change 
in the measured drug content (p>0.05) (Table 5-10) at the four different studied 
temperatures. However, there was a significant change in the drug content after three 
months at only 40°C (p<0.05). Also, after four months, there was a significant change at 
the four different studied temperatures (p<0.01 at 5°C and p<0.001 at 25°C, 30°C and 
40°C). From the obtained drug content results, it could therefore be suggested that our 
pregabalin-loaded ME eye drops should be stored at either 5°C or 25°C because the drug 
content didn’t change significantly and more than 90% of the pregabalin concentration 
remained in the formulation. Similarly, Zhu et al., (122) reported that penciclovir-loaded 
ME was stable at 4°C for 3 months with no significant change in physicochemical 
properties. Furthermore, previous studies proved the stability of ME-based 
dexamethasone eye drops for 3 months at °C (74). 
 
 
It has been reported that at least four half-lives are required to calculate the shelf 
life and the expiration date as well as the mechanism of drug degradation (123) so we 
were unable to determine these parameters yet as we did the stability study for four 
months where the formulation showed a good stability. The stability investigation of the 





Table 5-6.  Statistical comparisons among PDI values of pregabalin-loaded 
Carbopol ME eye drops stored at four different temperatures and the initial droplet 





1 month 2 months 3 months 4 months 
5°C 0.2741 0.9965 0.9940 0.9877 
25°C 0.9841 0.9990 0.9992 0.9988 
30°C 0.4356 0.9998 0.3777 0.9998 







Figure 5-4.  The zeta potential of pregabalin-loaded Carbopol ME eye drops at 
different temperatures after four months of stability study 
 
Data are expressed as mean±SD; n=3. 
After four months of stability study, there was no significant change in the zeta potential 





Table 5-7.  The average zeta potential of our prepared pregabalin-loaded ME eye 




Zeta potential (mV) 
5°C 25°C 30°C 40°C 
0 -31.42±1.14 -31.42±1.14 -31.42±1.14 -31.42±1.14 
1 -39.27±7.90 -36.89±1.43 -37.20±3.46 -38.90±1.31 
2 -31.77±2.49 -35.41±2.44 -41.99±0.90 -47.38±1.74 
3 -35.88±2.09 -41.39±1.35 -41.52±3.78 -48.36±0.40 





Table 5-8.  Statistical comparisons among the zeta potential values of pregabalin-
loaded Carbopol ME eye drops stored at four different temperatures and the initial 





1 month 2 months 3 months 4 months 
5°C 0.1069 0.9977 0.0798 0.3977 
25°C 0.3232 0.0764 0.0006 0.6428 
30°C 0.2796 0.0002 0.0005 0.6350 
40°C 0.1279 0.0001 0.0001 0.0450 
 





Table 5-9.  The percentage amount remaining of pregabalin in our prepared 





The percentage amount remaining of pregabalin 
5°C 25°C 30°C 40°C 
0 100±00 100±00 100±00 100±00 
1 100.00±1.23 100.00±0.88 100.00±1.98 100.00±4.17 
2 104.09±1.3 103.48±1.9 100.55±1.88 100.31±2.9 
3 96.76±4.9 92.21±2.1 86.25±1.2 82.54±12.6 





Table 5-10.  Statistical comparisons among the percentage amount remaining of 
pregabalin values of pregabalin-loaded Carbopol ME eye drops stored at four 





1 month 2 months 3 months 4 months 
5°C 0.9999 0.0702 0.9123 0.0013 
25°C 0.9999 0.1328 0.3877 0.0001 
30°C 0.9999 0.9878 0.0642 0.0001 
40°C 0.9999 0.9986 0.0192 0.0001 
 





In vitro release 
 
During the stability study of our pregabalin-loaded ME eye drops we thought to 
determine the ability of our multiple W/O/W ME system to maintain the sustained release 
pattern of pregabalin over the different studied periods at different temperatures. Figure 
5-5 showed the initial cumulative amount released of pregabalin up to 24 h (Figure 5-5 
A) and that after 1, 2, 3 and 4 months of stability study (Figure 5-5 B, C, D and E). 
Table 5-11 presented the statistical analysis of data at three time points during the in 
vitro release—2h, 8h and 24h. After four months, there was no significant difference 
(p>0.05) in the cumulative amount released of pregabalin from our ME eye drops stored 
at the four different temperatures compared to the initial data. However, after one, two 







Figure 5-5.  Cumulative amount released (%) of pregabalin from Carbopol ME 
eye drops (0.6%) at different temperatures after four month of stability study 
 
Data are expressed as mean±SD; n=3 
After four months, there was no significant difference (p>0.05) in the cumulative amount 
released of pregabalin from our ME eye drops stored at the four different temperatures 
compared to the initial data. However, after one, two and three months there was only 





Table 5-11.  Statistical comparisons among the cumulative amounts released of pregabalin after four months of stability and 






1 month  2 months  3 months  4 months 
2h 8h 24h  2h 8h 24h  2h 8h 24h  2h 8h 24h 
5° 0.3042 0.9999 0.9790  0.0071 0.1223 0.3494  0.9945 0.0634 0.7507  0.6733 0.2393 0.9105 
25°C 0.9961 0.7161 0.9627  0.0195 0.3445 0.9987  0.7015 0.1055 0.9965  0.8675 0.7128 0.3377 
30°C 0.7722 0.9999 0.9994  0.0109 0.0951 0.5088  0.9028 0.1158 0.9806  0.9998 0.2317 0.9364 
40°C 0.0192* 0.0933 0.6987  0.0015 0.0072 0.0876  0.3149 0.0223 0.7784  0.5769 0.0975 0.3103 
 










Although topical application of eye drops is an ideal approach to treat various eye 
diseases affecting the anterior segment of the eye, several drawbacks of these 
conventional ophthalmic formulations arise because of extensive precorneal loss that will 
end with low bioavailability. Therefore, several strategies have been designed to address 
these drawbacks as an attempt to improve bioavailability of topically applied drugs. In 
the pharmaceutical field, microemulsion have been widely used to enhance corneal drug 
penetration, increase drug loading, improve drug stability and bioavailability. Glaucoma 
as a progressive optic neuropathy with an elevated intraocular pressure as a major risk 
factor is the second cause of blindness in the world. Hence, lowering the IOP is the only 
target of the currently available glaucoma drugs. In our recently published work, we 
identified a new candidate gene, Cacna2d1, that modulates IOP and a promising 
therapeutic, pregabalin, which binds to CACNA2D1 protein and lowers IOP significantly 
in both mice and rabbits. Although in our study we proved the IOP-lowering efficiency of 
pregabalin in a dose dependent manner, several dosings of simple aqueous pregabalin eye 
drops is required because of short duration of action. Unfortunately, the hydrophilicity of 
the drug might be the main reason for such a short duration of action. We hypothesized 
that a new topical microemulsion bioadhesive ophthalmic formulation can sustain the 
release of pregabalin as a novel glaucoma therapy. Thus, in this study we wanted to 
develop an optimized ME-based ocular preparation of pregabalin for glaucoma and test 
its ability to sustain the drug release as a once-daily eye drop. 
 
 
Aim 1: To optimize and develop a multiple W/O/W microemulsion eye drops 
 
Using aqueous titration method and ternary& pseudo-ternary phase diagram 
construction, we were able to determine the proper weight ratios of the oil phase, aqueous 
phase and surfactant & co-surfactant to prepare the primary W/O microemulsion. By 
selecting surfactant & co-surfactant with a hydrophilic-lipophilic balance values of ≤5 we 
were able to decrease the number of screened surfactants & co-surfactants to save our 
time efficiently. Hence, after a number of systems were tested a system including 30% 
w/w of Labrafac lipophile WL1349 as the oil phase, MilliQ water (20% w/w) as the 
aqueous phase and 50% w/w of Capryol 90 & soybean lecithin, 1:1 mixture as the non-
ionic surfactant/cosurfactant mixture, was prepared. To select the proper hydrophilic 
surfactant & co-surfactant to prepare the external aqueous phase, different combination 
systems with high HLB values (≥12) were tested to prepare the multiple W/O/W ME 
disperse system. Also, one of the strategies that we used for these studies was the 
incorporation of a bioadhesive polymer in the external aqueous phase of our multiple ME 
to increase the viscosity and the precorneal contact time of our ocular ME eye drops. 
 
In this work, we aimed to slow the release of pregabalin and hence increase its 




the predetermined pregabalin dose in the innermost aqueous phase of our developed 
multiple W/O/W ME system while incorporating the remaining dose (60%) in the 
external polymeric aqueous phase. By such a strategy, a slow pregabalin release with a 
prolonged contact time will achieve a long duration of action after a single dose 
application.  
 
Our Aim 1 studies were innovative for at least the following five reasons: 
 
1. We have used Labrafac lipophile WL 1349, a medium chain triglyceride ester as 
the oil phase during the development of our ME system because of having a high 
shelf stability and less susceptibility to oxidation compared to long chain 
triglycerides. 
 
2. We have utilized a non-ionic surfactant/cosurfactant mixture—Capryol 90 & 
soybean lecithin, 1:1 mixture—which has a high compatibility with the oil phase. 
 
3. We have included a bioadhesive polymer—chitosan, sodium alginate or Carbopol 
981—in the external aqueous phase to insure a prolonged contact time after a 
single dose application. 
 
4. We have designed the incorporation of pregabalin dose by such away that we can 
induce a short onset with a longer duration of action as we incorporated only 40% 
of the dose in the innermost aqueous phase while incorporating the other 60% of 
the dose in the external aqueous phase. 
 
5. We have successfully developed a multiple W/O/W ME bioadhesive eye drops 
using few synthesis steps with an ease preparation and scaling up with no need for 
a specific type of equipment. 
  
 
Aim 2: To characterize the prepared multiple W/O/W microemulsion eye drops 
 
Due to the several drawbacks of eye drops which are the most currently available 
ocular drug delivery system, we aimed to overcome these limitations by addressing two 
important criteria. The first was to sustain the drug release; and the second was to 
improve the formulation bioadhesiveness to prolong its corneal contact time. Here, in our 
research, we strived to achieve these two targets by incorporating pregabalin in a multiple 
W/O/W ME that included a bioadhesive polymer.  
 
Most ME published studies showed how ME had been successfully used to 
improve the bioavailability of poorly water-soluble drugs by increasing their solubility 
and hastening their release and absorption (70, 124, 125). On the contrary, in our project 
we succeeded to use ME to slow the drug release and delay its corneal transport. Because 
our drug is water soluble, we modified the ME composition to take the advantages of 
both ME types; the slow release behavior of the W/O type and the aqueous sensation of 




novel extended release formulation to deliver pregabalin (a new glaucoma medication) 
(24) with an expected excellent patient satisfaction.  
 
During the preparation of our multiple ME, pregabalin (40% of the dose) was 
dissolved in the internal aqueous phase and then emulsified in the oil phase to produce 
the primary W/O ME. The produced W/O ME was further emulsified in an aqueous 
viscous polymeric solution to produce the final multiple W/O/W bioadhesive ME. In this 
study, we hypothesized that the addition of specifically selected polymers (126) that have 
excellent bioadhesive properties—chitosan, sodium alginate and Carbopol—will increase 
the precorneal contact time of our ME eye drops and therefore can increase the 
pregabalin duration of action. Using this specific design, the drug was located in two 
different phases within the multiple ME; the innermost aqueous layer and the external 
polymeric aqueous phase. So, to be released, the drug from the internal aqueous phase 
must pass through two interfaces the inner W/O interface and the outer O/W interface 
after which it has to diffuse through the viscous polymeric matrix to be ready for 
transport through the corneal epithelium layer. Moreover, an initial fast release might be 
an outcome of the presence of this 60% of the drug dose in the external aqueous phase, 
which was ready to be released after diffusion within the polymeric network. Using such 
a strategy, we successfully delayed and sustained the pregabalin release from our 
optimized ME-based formulation while maintaining the advantages of simple easy 
application into the eye. This project represents a novel application of ME in ocular drug 
delivery for water-soluble drugs. 
 
Although the pregabalin corneal permeability has not been studied yet, being a 
class I drug according to the BCS provided us with an expectation of a relatively high 
corneal permeability as well. Here, we used fresh isolated New Zealand white rabbit 
corneas to measure pregabalin corneal permeability from our developed ME eye drops 
and pregabalin aqueous solution. By this way we can investigate if our ME system affect 
the drug corneal permeability or not. We used BSS-PLUS® irrigating solution as a 
receptor medium during the study. Such medium would be ideal to keep the cornea alive 
during the whole experiment (6h), since this medium has a similar composition to 
aqueous humor and was commonly used as a sterile intraocular irrigating solution due to 
its ability to maintain the anatomic and physiologic integrity of intraocular tissues. In our 
study as we expected pregabalin proved to have a relatively high corneal permeability 
that will result in a high ocular bioavailability. 
 
Since ME as a colloidal drug carrier was generally used to enhance drug corneal 
penetration for drugs that have low corneal permeability, in our study our ME 
formulation could maintain the high permeability associated with pregabalin with no 
significant difference.  
 
Because we want to investigate the IOP-lowering effect of our new developed ME 
eye drops in Dutch-belted rabbits, we wanted to test first if CACNA2D1—the pregabalin 
target protein—is expressed in these animals eye tissues and if yes which tissues of the 
eye. Similarly, the IHC results in Dutch belted rabbit eyes were in agreement with what 




was highly expressed in both the ciliary body (non-pigmented epithelium) and the 
trabecular meshwork so the mechanism through which pregabalin decreased the IOP 
might be through decreasing the aqueous humor production by the ciliary body or 
increasing its drainge through the trabecular meshwork or by both mechanisms.  
 
Our Aim 2 studies were innovative for the following reasons:  
 
1. We have developed a multiple ME eye drops as a promising carrier that 
succeeded to sustain the release of pregabalin up to 24 h.  
 
2. By using isolated New Zealand white rabbit corneas, we were able to measure for 
the first time pregabalin high corneal permeability that was successfully 
maintained by our ME new formulations. 
 
3. We have proved the localization of pregabalin target protein in areas associated 
with IOP modulation—the non-pigmented epithelium of ciliary body and the 
trabecular meshwork. 
 
4. We have utilized the IHC results to suggest the mechanism through which 
pregabalin successfully decreased the IOP as a promising glaucoma therapy. 
 
5. We developed a novel and fully validated ME-based pregabalin eye drops that can 
be used as a promising carrier for other water-soluble drugs. 
 
 
Aim 3: To determine the safety, in vivo efficacy and cell toxicity of our prepared 
multiple W/O/W microemulsion eye drops in Dutch belted rabbits and a human 
corneal limbal epithelial cell line 
 
Due to the slow progressive loss of vision with no obvious symptoms in most 
cases of glaucoma, a main focus of interest should be to develop a once-daily glaucoma 
eye drops to help to control the elevated IOP with a high patient convenience. Since our 
IHC results illustrated the localization of pregabalin target protein in Dutch belted eye 
tissues that modulate IOP, we used these animals to determine if our sustained release 
ME eye drops could maintain the IOP at a lower level for longer period of time after a 
single dose application. In addition, Dutch belted rabbits have a high IOP baseline before 
the application of our eye drops which can mimic the situation in case of glaucoma 
patients. In this study, we wanted to test if there was a significant difference between our 
multiple ME eye drops and the pregabalin aqueous eye drops in our previous studies by 
calculating the different pharmacodynamic parameters— Tmax, %Imax, Tend and AUC —at 
the end of the experiment. 
 
 Also, to test the safety of our ME eye drops, we examined rabbits eyes every hour 
for any sign of irritation such as redness, tearing, conjunctival swelling or corneal 
swelling as well as slit-lamp examination at the end of the study. In this study, a single 




IOP reduction that returned to baseline at 32.7±1.3h from application (AUC=169.9±13.4 
mmHg.h). However, in the absence of the ME system, the same drug produced only 
29.4±1.4% IOP reduction that returned to baseline at 9.3±0.7h (AUC=39±4 mmHg.h). 
Our results are expected to fundamentally advance the field of glaucoma ocular therapy. 
 
Our Aim 3 studies were innovative for the following reasons: 
 
1. We have successfully developed a once-daily ME eye drops as a new glaucoma 
therapy. 
 
2. Our developed ME eye drops have a good safety in both the intact animals—
Dutch belted rabbits—and the HCLE cell line (in vitro cytotoxicity). 
 
 
Aim 4: To determine the physical and chemical stability of our ME eye drops 
 
Because our developed pregabalin-loaded Carbopol 981 ME eye drops is a new 
drug product so to establish the different storage conditions we wanted to test its stability 
under different environmental conditions. So, we used the centrifugation tests as well as 
the freeze-thaw cycles test to evaluate the physical stability of our new pharmaceutical 
product. Also, we can easily study the chemical stability of our formulation by 
accelerated, intermediate and long-term stability tests at 40°C, 30°C, 25°C and 5°C, 
respectively. In this study the measurement of droplet size, PDI and zeta potential was a 
good tool to assess the ME system stability under each specific storage condition. In 
addition, the drug content was an important parameter to test the stability of the drug 
substance and determine any degree of degradation. 
 
Our Aim 4 studies were innovative for the following reasons: 
 
1. Our pregabalin-loaded Carbopol ME eye drops has an excellent physical stability 
under intermediate and long-term condition—at 5°C, 25°C, 30°C— for the whole 
period of stability study (4 months). 
 
2. Our new pharmaceutical ME eye drops was able to maintain its small droplet size 
and low PDI during the whole stability study (4 months) which confirmed its high 
stability. 
 
3. We provide the pharmaceutical industry with a novel once-daily glaucoma ME 





Glaucoma is the leading cause of irreversible blindness worldwide. Elevated IOP 
is one of the most significant risk factors contributing to visual field loss in POAG, the 




during the management of the disease to suppress or slow down the disease progression. 
Because of the importance of a tightly maintained IOP, coupled with the fact that IOP 
can be medically controlled, IOP reduction is the first-line therapeutic option in 
glaucoma. Unfortunately, current medications suffer from poor patient compliance due to 
their short half-life and low residence time on the cornea, which require topical 
application multiple times per day. Also they are associated with reduced efficacy and 
systemic side effects. All these gaps represent enormous unmet needs. In this study we 
succeeded to address most of these limitations associated with current drug therapies by 
developing our IOP-lowering sustained release bioadhesive topical ME eye drops. 
Characterization results proved that our new formulations were suitable for topical 
ophthalmic use.  
 
Despite being water-soluble, our ME formulations could enable pregabalin to be 
administered as a once-daily eye drops. In vitro release study showed that our ME 
sustained the drug release up to 24h. Moreover, cytotoxicity study using MTT assay 
proved the non-cytotoxicity of our ophthalmic formulations to the human corneal limbal 
epithelial cell line. Also, our formulations had a reasonable viscosity, which was very 
important to prevent their precorneal loss from the eye surface for a while in order to give 
the chance for the bioadhesive interaction to occur to help the formulations to stick to the 
eye surface for more than one day. Furthermore, the bioadhesive study proved that the 
ME possessed high bioadhesive force than the controls. In addition, the corneal 
permeability experiment showed that our ME eye drops could maintain the high 
pregabalin corneal permeability (BCS class I drug) while controlling the drug release. 
Also, immunohistochemistry results demonstrated that CACNA2D1 was prominently 
localized in areas associated with aqueous humor modulation; both the CB and TM 
tissues of Dutch belted rabbits eyes. Moreover, the in vivo study of pregabalin ME eye 
drops on Dutch belted rabbits proved that only one drop of the ME could keep the IOP at 
lower level for up to 32.7±1.3h with 42.3±2.6% IOP reduction, which suggested its once-
daily application as a new glaucoma therapy. Finally, we can conclude that our ME eye 
drops could serve as a novel promising ocular drug delivery system that could sustain the 
drug release and prolong the duration of action not only for pregabalin but also for any 
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